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Abstract 
 
Innate lymphoid cells (ILCs) are tissue resident cells that play important roles in the 
maintenance of tissue homeostasis and the regulation of inflammation. ILCs have been 
extensively characterized in various organs such as the gut and the liver, revealing its diversity 
and tissue-specific specialization. However, whether ILCs are present in the central nervous 
system (CNS) and if so, what are their phenotype and function in this unique organ are 
questions that remain unanswered. NK cells are the longer-known and better-studied ILC 
members that share many phenotypical and functional features with ILC1s, making the 
distinction between these two subsets difficult. In particular, both mouse NK cells and ILC1s 
express NK1.1 and NKp46, secrete IFN-γ and contribute in the host defense against tumors 
and intracellular infections. In the context of autoimmunity, NK cells have been shown to 
display immunomodulatory roles, particularly in multiple sclerosis (MS), the most common 
inflammatory autoimmune disease of the CNS. Using the animal model of MS, the 
experimental autoimmune encephalomyelitis (EAE), our group showed that protective mature 
NK cells are recruited to the CNS on an CX3CR1-dependent manner. Based on that 
observations, my PhD project aimed to 1) define the chemokine receptors that mediate the 
recruitment of the immature NK cells into the inflamed CNS and to 2) determine whether the 
phenotypically defined NK cells (CD3-NK1.1+ cells) that are present in the CNS during steady 
state constitute bona fide NK cells or constitute also other group 1 ILC subsets.  
The results of the present work indicate that the CD3-NK1.1+ cells present in the healthy 
CNS comprise diverse group 1 ILC subsets that include the conventional NK cells, ILC1s, 
intermediate-ILC1s and ex-ILC3s. CXCR3 was expressed on ILC1s and a fraction of immature 
NK cells, but did not contributed to the recruitment of NK cells into the CNS in the EAE model. 
Instead, CXCR3 was downregulated in NK cells and ILC1s during inflammation, indicating a 
ligand induced internalization. Furthermore, the phenotypic and functional characterization of 
the newly identified CNS-ILC1s substantiated their identity as a separate subset from 
conventional NK cells. The exclusive expression of CD49a, CD69, CXCR6, DNAM-1high, TRAIL 
and CD200R, and lack of Eomes distinguished the ILC1s from the NK cells in the CNS. In 
addition, ILC1s secreted IFN-γ and more TNF-α than NK cells upon stimulation in the healthy 
and EAE mice. ILC1s were the dominant group 1 ILC subset in the choroid plexus and brain 
parenchyma and were also present in the meninges. During EAE, in addition to CXCR3, the 
expression of TRAIL was downmodulated, and an increase in the numbers of all group 1 ILCs 
was observed in the brain parenchyma. However, contrary to NK cells, ILC1s did not proliferate 
during EAE suggesting an in situ NK cell to ILC1 differentiation. In sum, the present work 
provides for the first time a comprehensive characterization of group 1 ILCs in the CNS, which 
reveals a possible gatekeeper and neuroprotective role of ILC1s in this unique organ.  
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Zussamenfassung 
 
Angeborene lymphoide Zellen (ILCs) sind sich im Gewebe befindliche Zellen, die eine 
wichtige Rolle bei der Aufrechterhaltung der Gewebehomöostase und der Regulation von 
Entzündungen spielen. ILCs wurden in verschiedenen Organen wie dem Darm und der Leber 
umfassend untersucht und zeigten eine hohe Diversität und gewebespezifische 
Differenzierung. Ob ILCs im zentralen Nervensystem (ZNS) vorhanden sind und wenn ja, 
welchen Phänotyp und welche funktionellen Eigenschaften sie in diesem einzigartigen Organ 
aufweisen, sind Fragen, die bisher unbeantwortet blieben. NK-Zellen sind die seit langem 
bekannten und besser untersuchten ILC-Mitglieder, die viele phänotypische und funktionelle 
Merkmale mit ILC1s teilen. Es macht die Unterscheidung zwischen diesen beiden 
Untergruppen schwierig. Sowohl Maus-NK-Zellen als auch Maus-ILC1s exprimieren NK1.1 
und NKp46. Beide sezernieren IFN-γ und tragen zur Abwehr von Wirten gegen Tumore und 
intrazelluläre Infektionen bei. Im Zusammenhang mit der Autoimmunität wurde gezeigt, dass 
NK-Zellen eine immunmodulatorische Rollen spielen. Dies wird besonders bei Multipler 
Sklerose (MS), der häufigsten entzündlichen Autoimmunerkrankung des ZNS, klar. Anhand 
des Tiermodells von MS, der experimentellen autoimmunen Enzephalomyelitis (EAE), zeigte 
unsere Gruppe, dass reife NK-Schutzzellen auf CX3CR1-abhängige Weise in das ZNS 
rekrutiert werden. Auf der Grundlage dieser Beobachtungen will ich in meinem PhD Projekt 
die Chemokinrezeptoren definieren, die die Rekrutierung der unreifen NK-Zellen in das 
entzündete ZNS vermitteln. Des Weiteren will ich herausfinden, ob die phänotypisch 
definierten NK-Zellen (CD3-NK1.1 + -Zellen) im gesunden ZNS vorhanden sind und ob dies 
echte NK-Zellen sind, oder sie zu den ILC1s gezählt werden können. 
Die Ergebnisse der vorliegenden Arbeit zeigen, dass die im gesunden ZNS vorhandenen 
CD3-NK1.1+ -Zellen verschiedene Typ-1-ILC-Subsets umfassen, die die herkömmlichen NK-
Zellen, ILC1s, Intermediat-ILC1s und Ex-ILC3s umfassen. CXCR3 wurde auf ILC1s und einer 
Fraktion von unreifen NK-Zellen exprimiert, trug jedoch nicht zur Rekrutierung von NK-Zellen 
in das ZNS im EAE-Modell bei. Stattdessen wurde CXCR3 während der Entzündung in NK-
Zellen und ILC1-Zellen herunterreguliert. Was auf eine, durch den Liganden induzierte, 
Internalisierung hindeutet. Die phänotypische und funktionelle Charakterisierung der neu 
identifizierten ZNS-ILC1s untermauert ihre Identität als separate Untergruppe von 
herkömmlichen NK-Zellen. Die ausschließliche Expression von CD49a, CD69, CXCR6, 
DNAM-1high, TRAIL und CD200R und das Fehlen von Eomes unterschieden die ILC1 von 
den NK-Zellen im ZNS. Zusätzlich sezernierten ILC1s bei Stimulation in den gesunden und 
EAE-Mäusen IFN-γ und mehr TNF-α als NK-Zellen. ILC1s waren die dominante Typ-1-ILC 
Subgruppe im Plexus choroideus und im Gehirnparenchym und waren auch in den Meningen 
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vorhanden. Während der EAE wurde zusätzlich zu CXCR3 die Expression von TRAIL 
herunterreguliert, und im Gehirnparenchym wurde ein Anstieg der Anzahl aller Typ-1-ILCs 
beobachtet. Im Gegensatz zu NK-Zellen proliferierten ILC1s jedoch nicht während der EAE, 
was eine In-situ-NK-Zelle für die ILC1-Differenzierung vermuten lässt. Zusammenfassend 
bietet die vorliegende Arbeit zum ersten Mal eine umfassende Charakterisierung von ILCs des 
Typs I im ZNS, die eine mögliche Gatekeeper und neuroprotektive Rolle von ILC1s in diesem 
einzigartigen Organ aufzeigen könnte. 
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1 List of abbreviations 
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ADCC 
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APC (fluorophore)  
APC (immunity) 
BBB 
BM 
BrefA 
BSA  
BV 
CCL  
CCR  
CD  
CFA 
CMV 
CNS  
CP 
CSF 
CX3CL  
CX3CR  
CXCL  
CXCR 
DNA 
DC  
DNAM-1  
DNase  
EAE  
EDSS  
Eomes   
FACS  
Fc 
FcR 
FCS 
 
7-aminoactinomycin 
antibody dependent cell cytotoxicity 
alexa fluor 
allophycocyanin 
antigen presenting cell 
blood brain barrier 
bone marrow 
brefeldine A 
bovine serum albumin 
brilliant violet 
CC chemokine ligand 
CC chemokine receptor 
cluster of differentiation 
complete Freund’s adjuvant 
cytomegalovirus 
central nervous system 
choroid plexus 
cerebrospinal fluid 
CX3C chemokine ligand 
CX3C chemokine receptor 
CXC chemokine ligand 
CXC chemokine receptor 
deoxyribonucleic acid  
dendritic cell 
DNAX accessory molecule I 
deoxyribonuclease 
experimental autoimmune encephalomyelitis 
expanded disability status scale 
eomesodermin 
flow activated cell sorting 
constant fraction 
constant fraction receptor 
fetal calf serum 
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FITC  
FSC 
g 
GFP  
GM-CSF  
gMFI 
HLA  
HSC 
IFN 
Ig 
IL 
ILC 
intILC 
KIR  
LN  
LTi 
MACS  
MMP  
MOG   
MRI  
MS 
NCR 
Nfil3  
NK 
NKG2  
NKp 
NSC 
p.i. 
PacBlue 
PBS 
PE 
PE Cy7 
PerCPCy5  
PFA 
PLP 
PMA 
p-value 
fluorescein isothiocyanate 
forward scattered light 
relative centrifuge force (g = 9.81 m/s2) 
green fluorescent protein 
granulocyte-macrophage colony-stimulating factor 
geometric mean fluorescence intensity  
human leukocyte antigen 
hematopoietic stem cell 
interferon 
immunoglobulin 
interleukin 
innate lymphoid cell 
intermediate innate lymphoid cell 
killer cell immunoglobulin-like receptor 
lymph nodes 
lymphoid tissue inducer 
magnetic activated cell sorting 
matrix metalloproteinase 
myelin oligodendrocyte glycoprotein 
magnetic resonance imaging 
multiple sclerosis 
natural cytotoxicity receptor 
nuclear factor, interleukin 3 regulated 
natural killer 
killer cell lectin-like receptor subfamily K 
natural killer cell p-related protein 
neural stem cell 
post immunization 
pacific blue 
phosphate buffered saline 
phycoerythrin 
phycoerythrin cyanine 7 conjugate 
peridinin chlorophil protein complex cyanine 5 
conjugate 
paraformaldehyde 
myelin proteolypic protein 
phorbol 12-myristate 13-acetate 
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RFP 
RNA 
ROS 
rpm 
RRMS 
RT 
S1P 
S1P1 
SEM 
SJL  
SSC 
SVZ 
T-bet 
TGF 
Th   
TNF  
TRAIL 
Treg  
WT 
probability value 
red fluorescent protein 
ribonucleic acid 
reactive oxygen species 
revolutions per minute 
relapsing remitting multiple sclerosis 
room temperature 
sphingosine-1-phosphate  
sphingosine-1-phosphate receptor 1 
standard error of the mean 
Swiss Jim Lambert  
sideward scattered light 
subventricular zone 
t-box transcription factor TBX21 
transforming growth factor 
T helper cell 
tumor necrosis factor 
TNF-related apoptosis-inducing ligand 
regulatory T cell 
wild type 
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3 Introduction  
 
3.1 Overview of the immune system and its innate and adaptive arms 
 
Biological organisms are continuously exposed to a myriad of potential pathogens. One 
of the key evolutionary assets of all organisms was the development of a mechanism by which 
those threats could be identified and eliminated. This mechanism is what we call the immune 
system, manifested in different ways in bacteria, plants, fungi, invertebrates and vertebrates.  
In vertebrates, the immune system is classically divided into the innate and the adaptive 
arm. The innate immune system represents the first line of defense and is considered to be 
fast, unspecific and not memory generating. The innate immunity consists of anatomical 
barriers like the skin; a humoral component, like the complement system and coagulation 
cascade; and a cellular component. The main cellular components of the innate immunity are 
the macrophages, neutrophils, dendritic cells, natural killer cells and the recently discovered 
innate lymphoid cells. They possess pattern recognition receptors on their surface that 
recognize molecular patterns common in pathogens, injured and transformed cells. This 
receptor activation leads to a fast response that results in the secretion of inflammatory 
molecules including chemokines and cytokines that attract and regulate the function of other 
immune cells. In addition, the innate immune cells are able to directly eliminate pathogens by 
different mechanisms such as phagocytosis or cytotoxicity. Due to its early response, the 
activity of the innate immunity shapes the nature of the adaptive immune response.  
The adaptive immune system, also known as acquired or specific immune system, is 
mainly comprised of T and B lymphocytes. Their key features are their specificity, conferred 
by a huge variety of antigen-specific receptors; and their capacity to generate immunological 
memory, which is the ability to mount a fast response after the exposure of a previous 
encountered antigen, for instance, after re-infection with the same pathogen. The humoral 
component of the adaptive immune system are the antibodies, produced by the B cells. 
Antibodies bind specifically to antigens contributing to pathogen clearance in different ways, 
for example by tagging them for recognition by phagocytes or activating the complement 
system. In contrast to the innate immune system, in which pattern recognition receptors are 
encoded in the germline, the antigen-specific receptors of the T and B lymphocytes are 
generated in the cell during the lifetime of the organism by a process of somatic recombination. 
In this way, a few hundred different gene segments are recombined in different ways to 
generate thousands of different receptors (1). When a T or B cell receptor binds to its antigen, 
a process of clonal expansion that lasts several days starts until the cell mature into an effector 
cell. Once the antigen is removed, some cells persist in the form of memory cells that will react 
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quicker to the next infection with the same antigen. The immune response has to be tightly 
regulated to avoid collateral damage and the development of autoimmunity. Therefore, various 
subsets of cells are specialized in curving the immune response. Among them, the regulatory 
T cells (Tregs) are the most notable immunosuppressive cells. Moreover, both innate and 
adaptive immune cells possess regulatory functions.  
The immune cells are generated in the bone marrow from hematopoietic stem cells 
(HSC), where most of them also mature (1). T cells, in contrast, undergo a maturation process 
in the thymus. The process of hematopoiesis gives rise to all cellular components of the blood 
including the red blood cells. In this process, the HCS differentiate into a myeloid progenitor or 
a lymphoid progenitor. The common myeloid progenitor cells further differentiate to give rise 
to granulocytes (i.e neutrophils, basophils and eosinophils), monocytes (macrophages and 
dendritic cells) erythrocytes and mast cells. On the other hand, the common lymphoid 
progenitor cells differentiate into T and B lymphocytes, NK cells and innate lymphoid cells.  
Mature immune cells travel through the lymphatic system and the blood stream and 
come together in the secondary lymphatic organs such as the spleen and lymph nodes. The 
lymph nodes are connected with an extended network of lymphatic vessels and capillaries that 
span the whole body and drain fluid from the tissues and blood. It was long believed that the 
central nervous system was the only structure that lack a lymphatic drainage. However, a 
meningeal lymphatic system that drains cerebrospinal fluid to the deep cervical lymph nodes 
was recently discovered (2). In the lymph nodes, innate and adaptive cells reside and act in 
concert in highly organized structures, encounter survival signals, and are activated by antigen 
presenting cells (APCs) to induce an immune response.  
In addition to the classical lymphoid organs, it has been increasingly recognized that 
other organs like the lung and the liver contain immune cell niches and perform immune 
functions. For example, the liver is a repository of numerous innate and adaptive immune cells. 
Also, it has a key role in the detection and clearance of pathogens from blood, and has a major 
role in eliminating activated T cells (3,4). In the case of the lung, it was shown that it can serve 
as a site of memory and effector T cell reactivation (5). In addition, it is the organ with the 
highest frequency of NK cells among other lymphocytes (6).  
In fact, all tissues possess resident immune cells that continuously scan the environment 
and participate in immune defense. The most recent type of tissue resident immune cell 
described are the innate lymphoid cells (ILCs). Intensive research in the biology of ILCs in the 
last decade has deepened our appreciation of the many roles of the immune system in 
functions as diverse as tissue morphogenesis, regeneration and metabolism and their crucial 
interactions with the microbiome and the nervous system to maintain tissue homeostasis (7). 
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3.2 Innate lymphoid cells, the counterpart of T lymphocytes 
 
The establishment of the ILC family is very recent. The natural killer (NK) cells were the 
first members to be recognized in 1975 as cells that displayed spontaneous or “natural” 
cytotoxicity against tumor cells without previous immunization (8,9). The lymphoid-tissue-
inducer (LTi) cells were then described in the late nineties as essential cells for the 
development of lymph nodes and Peyer’s patches (gut associated lymphoid tissue) (10). 
Subsequently, newly discovered unorthodox innate immune cells were given various names 
like the interleukin (IL)-22-producing mucosal NK-22 cells (11) or the IL-13-producing nuocytes 
(12). Finally, a proposal for a uniform nomenclature in 2013 (13) categorized these cells into 
three different groups that mirror the classification of T cells. Those are the group 1 ILCs that 
include the NK cells and ILC1s; the group 2 ILCs composed by the ILC2s; and the group 3 
ILCs that include the LTis and the natural cytotoxicity receptor (NCR) positive and negative 
ILC3s. The latest update in the classification expand it into five subsets – NK cells, ILC1s, 
ILC2s, ILC3s and LTis – based on their developmental trajectories (7). The ILC1s, ILC2s, 
ILC3s and LTi are collectively referred as helper ILCs and are specially enriched in mucosal 
tissues. In the present thesis, I will refer collectively to NK cells and ILC1s as group 1 ILCs. 
The ILC classification applies for both human and mice. Although helper ILCs have been more 
extensively studied in mouse models, the presence of all ILC groups have been confirmed in 
humans multiple times (summarized in (14). However, some aspects of human ILC 
development does not seem to be the same as in mice and requires further refining (14). 
ILCs, like the T and B cells, originate from the common lymphoid progenitor (CLP), but 
in contrast to their adaptive counterpart, they lack rearranged antigen-specific receptors. The 
CLP gives rise to the innate lymphoid progenitor (CILP) that differentiates into the NK cell 
precursor (NKP) or the common helper innate lymphoid precursor (CHILP). The CHILP in turn, 
differentiates into the LTi precursor (LTP) and the ILC precursor (ILCP) from which the ILC1, 
ILC2 and ILC3s develop. Each differentiation step requires the expression of a set of 
transcription factors depicted in Figure I. In contrast to NK cells, helper ILCs require the 
expression of the transcription factor GATA-3 for their development (Yagi 2014) and are 
phenotypically defined by the surface expression of IL-7 receptor alpha (IL-7Ra) or CD127. IL-
7 is required for the maintenance of ILCs, and its deficiency (or IL-7Ra deficiency) largely 
reduce the number of ILC2s and ILC3s in the tissues (15). In turn, IL-15 is more important for 
ILC1 and NK cell maintenance (16–18). 
The ILCs are considered as the innate counterpart of the T cells because their 
transcriptional programs and cytokine secretion mirror those of the different T cell subsets. The 
similarity in the effector functions of T cells and ILCs have raised the question of whether ILCs 
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have a “redundant” role in immunity. Indeed, the function of ILCs may overlap with their 
adaptive counterparts in many contexts. However, mounting research is showing that ILCs and 
T cells cooperate, relay and complement each other (19–22). Furthermore, the ILCs serve as 
an interface between the external environment and the adaptive immune system. Thus, the 
regulation of ILC functions is key in the maintenance of tissue homeostasis and the limitation 
of autoimmunity (23,24). 
 
 
Figure I. Development and function of ILCs. Precursor cells are shown in grey. The transcription 
factors needed for their differentiation are indicated in the arrows. Each subset secretes different effector 
molecules upon activation that mediate important immune functions. Abbreviations: CILPs (common 
innate lymphoid pro- genitors), CLPs (common lymphoid progenitors), CHILPs (common helper innate 
lymphoid progenitors), LTiPs (lymphoid tissue inducer progenitors), ILCP (innate lymphoid cell 
precursors), NFIL3 (nuclear factor IL-3 induced), Id2 (inhibitor of DNA binding 2), TOX (thymocyte 
selection associated high mobility group box protein), TCF-1 (T cell factor 1), ETS1 (avian 
erythroblastosis virus E26 homolog-1), GATA3 (GATA binding protein 3), PLZF (promyelocytic leukemia 
zinc finger), T-bet (T-box transcription factor), Eomes (Eomesodermin), RUNX3 (runt-related 
transcription factor 3), RORa (RAR-related orphan receptor a), Bcl11b (B cell lymphoma/leukemia 11B), 
Gfi1 (growth factor independent 1), RORγt (RAR- related orphan receptor γt), and AhR (Aryl hydro- 
carbon receptor). Figure based on schemas from (7).  
 
Next, an overview of each subset is presented, with special emphasis on the group 1 
ILCs (i.e. NK cells and ILC1s).   
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3.2.1 NK cells 
 
NK cells constitute the cytotoxic member of the ILC family and is thus considered to be 
the counterpart of the cytotoxic CD8+ T cells. Like the CD8+ T cells, NK cell development 
depends on the T-box transcription factor (T-bet) and Eomesodermin (Eomes) (25–27) and 
secrete the signature type I cytokine interferon gamma (IFN-γ). Also, IL-15 is essential for the 
development, homeostasis and function of NK cells (28,29). In addition, IL-12 and IL-18 play 
important roles in NK cell maturation and activation (30).  
NK cells are crucial in protecting the host against intracellular infections and cancer. They 
possess a vast array of inhibitory and activating receptors with which they recognize healthy 
from transformed cells. The balance between inhibitory and activating signals and the cytokine 
microenvironment determine the nature and intensity of the NK cell response. Healthy cells 
constitutively express major histocompatibility complex class I (MHC-I) receptors on their 
surface. NK cells are “educated” to tolerate these MHC-I-expressing self-cells by detecting 
them with their inhibitory receptors, such as the killer cell immunoglobulin-like receptors (KIRs) 
in humans, the lectin-like Ly49 dimers in the mouse and the lectin-like CD94-NKG2A 
heterodimers in both species (31). When they engage to MHC-I molecules, cell lysis is 
inhibited, but when stressed, tumoral or infected cells downregulate MHC-I membrane 
expression, the lack of inhibition activates NK cell cytotoxicity (32). In turn, cells in distress 
express ligands that can be recognized by activating receptors triggering NK cell cytotoxicity. 
Many of these receptors are conserved in mice and humans. In fact, NKp46 (natural 
cytotoxicity triggering receptor 1) serves as a prototypical marker of NK cells in various species 
ranging from mice to monkeys and humans (33). Cells that have been opsonized with 
antibodies can also be recognized by NK cells and elicit a cytotoxic response by interacting 
with the Fc-receptor CD16 in a process called antibody-dependent cellular cytotoxicity (ADCC) 
(34). NK cells exert their killing abilities by releasing granules that contain perforin and 
granzymes. Perforin is a pore-forming protein and granzymes are proteases that together 
induce target cell apoptosis by activating caspases and damaging mitochondria and DNA (35). 
In addition, NK cells upregulate the apoptosis inducing ligands FasL and TRAIL upon activation 
(36). Besides being effective killing machines, NK cells produce cytokines and influence the 
function of other immune system cells. NK cells produce immunoregulatory cytokines including 
IFN-ɣ, tumour necrosis factor-alpha (TNF-α), IL-10 and granulocyte-macrophage colony 
stimulating factor (GM-CSF). They stimulate other innate immune system cells such as 
neutrophils and macrophages and shape the T cell response. Monocyte and dendritic cell 
derived cytokines IL-12, IL-15 and IL-18 as well as the T cell derived IL-2 modulate NK cell 
proliferation, maturation and function (31,37–39). 
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In the last years, it has emerged that NK cells display adaptive features in both human 
and mice. In particular, it has been shown that a subset of NK cells that recognizes 
cytomegalovirus (CMV) infected cells via the Ly49H receptor in mice and the NKG2C receptor 
in humans, display memory features. This subset of NK cells expands upon activation, 
contracts and differentiates into a long-lived memory subset that persist several months and is 
able to mount a recall response to a CMV reinfection, protecting the host better than naïve NK 
cells (40–42).  
Different maturation and functional NK cell subsets have been described in both humans 
and mice. In humans, NK cells are phenotypically defined by the expression of CD56 and 
CD16. The CD56dimCD16+ NK cells display a high cytotoxic activity, while the CD56brightCD16- 
NK cells have a lower cytotoxic potential but proliferate more readily upon stimulation and 
secrete higher amounts of cytokines (43). The CD56bright subset is considered the immature 
subset as they can differentiate into CD56dim cells (44,45).  
Mouse NK cells lack CD56 expression and are phenotypically defined by the expression 
of the natural cytotoxicity receptors NKp46 and NK1.1 depending on the mouse strain. The 
mouse strain used in the present study, C57BL/6, expresses both the NKp46 and NK1.1. The 
integrin CD49b (also known as DX5 or a2b1 integrin) is also constitutively expressed in NK 
cells and its expression was shown to be dependent on Eomes (26), which also regulates the 
expression of other NK cell-specific genes like Gzmb (Granzyme B) and Prf17 (Perforin) (46). 
Therefore, surface markers associated with Eomes expression, such as CD49b, represent 
reliable markers to distinguish NK cells from other ILC subsets.  
The maturation subsets of NK cells can be distinguished by the expression of CD27 and 
CD11b. First, NK cells acquire the expression of CD27 and as the cell matures CD11b is 
expressed and CD27 is lost. Hence, the sequential developmental stages are divided as 
follows: CD27-CD11b-, CD27+CD11b, CD27+CD11b+ and CD27-CD11b+ (47). For simplicity, 
the immature NK cells can be designated as CD11b- and the mature as CD11b+. Similar to 
the human, immature CD11b- NK cells are more proliferative, secrete more cytokines and 
possess lower cytolitic granules than the mature CD11b+ NK cells (47,48). 
DNAM-1 (DNAX accessory molecule, CD226) is another marker proposed to identify the 
maturation status of NK cells. DNAM-1 is an adhesion and costimulatory molecule that binds 
to the poliovirus receptor ligands nectin-2 (CD112) and PVR (CD155) (49). It plays important 
roles in mediating NK cell functions, like cytotoxicity against tumors, secretion of IFN-γ and 
generation of memory NK cells (50–53). It was shown that DNAM-1+ NK cells could be 
considered immature since they can differentiate into DNAM-1- NK cells. The DNAM-1+ cells 
are more proliferative, cytotoxic and secrete more cytokines than the DNAM-1- NK cells, which 
secrete more chemokines and were assigned a sentinel function (54).  
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3.2.2 ILC1s 
 
ILC1s and NK cells share many similitudes. In fact, ILCs have been mistaken by NK cell 
for many years, for example, the liver ILC1s were initially thought to represent immature NK 
cells (55). Like NK cells, ILC1s express NKp46 and NK1.1, secrete IFN-γ and depend on T-
bet and IL-15 for their development. However, ILC1s do not need Eomes for their development, 
possess low cytolitc granules and thus are considered non-cytotoxic. ILCs are deemed to 
contribute to the immune response by secreting higher levels of cytokines than NK cells 
including TNF-α, GM-CSF and IL-2 (7,56,57). However, ILC1s usually express the apoptosis 
inducing ligand TRAIL and accordingly, it has been shown that ILC1s can mediate TRAIL-
dependent tumor killing in the liver (58).  
Eomes expression is important to repress the integrin CD49a (alpha 1) and induce 
CD49b, therefore, ILC1s express only CD49a, which is used as a marker to distinguish them 
from NK cells (17,27). ILC1s express other ILC-specific markers like CD90 and CD127 (59). 
However, the expression of CD127 in ILC1s is more heterogeneous than initially assumed. For 
example, the gut lamina propia ILC1 are CD127+ while the gut intraepithelial ILC1s are CD127- 
(60). In the liver, only a fraction of the ILC1s express CD127 (61). Recently, the inhibitory 
CD200R1 was proposed to be a useful marker to discriminate ILC1s, as it is not expressed in 
NK cells (62). Furthermore, ILC1s express the transcription factor Hobit (also known as 
Zfp683), which has been implicated in controlling lymphocyte tissue-residency and survival 
(63). Hobit-deficient mice exhibit a specific reduction in liver ILC1s as thus has served as a 
model of ILC1 deficiency (62), although a more comprehensive analysis of the effect of Hobit 
deficiency in other organs is still needed..  
ILC1s are essential for clearance of viral infections and other intracellular and 
extracellular pathogens like the parasitic protozoan Toxoplasma gondii and the bacteria 
Clostridium difficile. In the case of viral infections, it was demonstrated with a mouse model of 
CMV infection that ILC1s provide the earliest source of IFN-γ to the infected tissues including 
the sites of entry like the lung, skin and mouth and the sites of infection like the liver and spleen. 
This was crucial to restrict virus replication and dissemination and improved host survival. 
Interestingly, the group also showed ILC1s are more responsive to IL-12 than NK and NKT 
cells in the liver (62). In T gondii infection, IFN-γ contribute to the recruitment of inflammatory 
monocytes (Schulthess 2012) and induce reactive oxygen species (ROS) in infected cells, 
restricting parasite replication and growth (64). ILC1s produce IFN-γ and TNF-α and limit T. 
gondii replication in the intestine (17,60,65). Host defense against C. difficile acute infection 
also requires ILC1-derived IFN-γ (66). On the other hand, ILC1-derived IFN-γ can also have 
detrimental effects in some contexts. For example, it was shown that in the adipose tissue, the 
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ILC1s proliferate and accumulate during high fat diet, producing IFN-γ and contributing to the 
polarization of M1 macrophages, which are associated with obesity-induced insulin resistance 
(67).  
In the context of tumor microenvironment using mouse models of primary and 
transplantable tumors, it was shown that ILC1s were unable to restrain tumor growth and 
metastasis, in contrast to NK cells, which played a critical protective role (68). However, a 
subset of “cytolitic ILC1s” have been described in various organs that are able to mount strong 
cytotoxic responses against tumors. Contrary to conventional NK cells and helper ILC1s, the 
cytolitic ILC1s do not depend on the transcription factor Nfil3 for their development (69–71) 
and their ontogeny is yet to be elucidated. 
 
3.2.3 ILC2s 
 
ILC2s are the counterpart of Th2 cells. As such, they mount type 2 immune responses 
that are specialized in protecting the host against large allergens and parasitic worms. ILC2s 
depend on GATA-3 and retinoic acid receptor-related orphan receptor-α (ROR-α) for their 
development and function. The cytokine IL-7 is also necessary for their development. ILC2s 
produce the cytokines IL-4, IL-5, IL-9 and IL-13 and respond to IL-25, IL-33 and thymic stromal 
lymphopoietin (TSLP). They are enriched in barrier surfaces such as the skin, lung and 
intestine and can be recognized by the expression of CD90, CD127 and the IL-33 receptor 
subunit T1-ST2 (7). ILC2s are essential in the coordination of the immune response against 
parasitic worms such as Nippostrongulus brasiliensis. The cytokines they secrete regulate 
monocyte and granulocyte responses and induce smooth muscle contractility that promote 
parasite expulsion (72,73). Furthermore, ILC2s are associated with tissue repair by producing 
the ligands for the epithelial growth factor receptor such as amphiregulin, which is required for 
epithelial cell differentiation and proliferation, as shown in a model of intestinal inflammation 
(74) and influenza-induced tissue damage in the lung (75). Interestingly, ILC2s are 
constitutively present in visceral adipose tissue where they can regulate adiposity and insulin 
resistance (76).  
 
3.2.4 ILC3s 
 
ILC3s are the counterpart of Th17 cells, which are involved in the immune response to 
extracellular bacteria. They depend on the transcription factor retinoic acid receptor-related 
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orphan receptor-γt (RORγt) for their development and secrete the cytokines IL-17 and IL-22. 
ILC3s are activated by IL-23 and IL-1β and predominantly reside in mucosal tissues. ILC3s 
express the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor that acts 
as an environmental sensor, as it is activated by various compounds including toxins, 
tryptophan metabolites, dietary products and bacterial pigments (73). AHR activation controls 
the survival of ILC3s (77), and is essential in maintaining gut homeostasis. For example, the 
activation of AHR by tryptophan metabolites from commensal bacteria induce the secretion of 
IL-22 and antimicrobial peptides that prevents bacterial dissemination and inappropriate 
immune responses against them (78,79). In addition, ILC3s can promote a tolerogenic state in 
the gut by regulating T cells responses against commensal bacteria (21). IL-22-producing 
ILC3s are also critical for defense against bacterial infections such as Citrobacter rodentium, 
which is the mouse equivalent of human Escherichia coli infection that causes acute colitis 
(80,81). This cytokine also promotes tissue repair and regeneration in the inflamed intestine 
(Sawa 2011) and limits tissue damage in allergic lung disease (82). 
ILC3s are CD127+ and can be divided in NCR+ and NCR- ILC3s. NCRs include NKp46 
and NKp30 in humans and mice and NKp44 in mice. NKp46+ ILC3s were first discovered and 
described as atypical NK cells derived from the LTis (83,84). The distinction in the function 
between these two subsets is not clear, however, NKp46+ ILC3s have been shown to have 
anti-tumor properties (85–87). 
 
3.2.5 LTi cells 
 
Lymphoid tissue inducer cells depend, like the ILC3s, on the transcription factor RORγt 
but arise from a different progenitor than the rest of the helper ILCs. LTi cells are CD127+ and 
depend on IL-7 for their survival and differentiation (88). LTi cells are NCR-, express the 
chemokine receptor CCR6 and a subset is CD4+. LTi cells are present early in fetal 
development and coordinate the formation of lymph nodes and Peyers patches (10,89). LTi 
cells produce lymphotoxins that induce the secretion of chemokines and adhesion molecules 
in stroma organizer cells, which attract lymphocytes during fetal development to form lymphoid 
structures (90).  After birth, LTi-derived lymphotoxins regulate gut immunity (22).  
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3.2.6 ILC plasticity and heterogeneity  
 
One of the features that have raised interest in the study of ILC subsets is their plasticity, 
that is, the ability of one ILC subset to differentiate into a different ILC subset. ILCs exhibit 
tissue specific characteristics and dynamically respond to the stimuli present in the tissue 
microenvironment by regulating their phenotype and function (87). Furthermore, a great 
heterogeneity can be found within an individual ILC subset, as it was revealed in single cell 
transcriptome analysis of the ILCs present in the small intestine lamina propria (91). In that 
study, the authors found four ILC1, four ILC2 and five ILC3 functional subsets based on their 
transcriptional profiles. Interestingly, some of these sub-subsets were altered after microbiome 
manipulation, corroborating the dependency of ILC phenotype and functionality on tissue 
microenvironment signals.  
TGF-β can drive the differentiation of NK cells into ILC1s. TGF-β signaling repress 
Eomes and induces the expression of ILC1 markers such as CD49a and TRAIL (92). 
Interestingly, in the TGF-β-rich tumor microenvironment, an intermediate subset that express 
both CD49a and CD49b was found, termed intermediate-ILC1s (intILC1s). This subset 
displays features of both NK cells and ILC1s and exhibits a higher proliferation rate (68). It is 
therefore possible that the conversion of NK cells into ILC1s after TGF-β stimulation goes 
through an intILC1 stage.  
Another notable example of ILC plasticity is the ability of ILC3s to convert into ILC1s. 
After IL-12 stimulation, ILC3s downregulate RORγt and upregulate Tbet and NCR expression 
acquiring the ability to secrete IFN-γ (65,93,94). The ILC1s derived from an ILC3 lineage have 
also been called “ex-ILC3s. ILC1s can in turn differentiate into ILC3s after IL-23, IL-1b and 
retinoid acid (RA) stimulation (11,95). This conversion of “homeostatic” IL-22-producing ILC3s 
into “inflammatory” IFN-γ-producing ILC1s was shown to be important to fight Salmonella 
infection in the gut. However, ILC1s also promoted enterocolitis (94). In line with this, an 
accumulation of ILC1s was found in the inflamed intestine of Crohn's disease patients (65).  
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Figure II. Plasticity of NK cells, ILC1s and ILC3s. Stimulation with IL-12 can induce ILC3s to adopt 
an ILC1 phenotype (exILC3) with a corresponding downregulation of RORγt and upregulation of T-bet. 
In turn, differentiation of ILC1s into ILC3 can be induced by IL-23 stimulation and accelerated by IL-1b 
and RA. NK cells can adopt an intILC1 or ILC1 phenotype in response to TGF-β stimulation. It remains 
unclear whether intILC1s differentiate into ILC1s.    
 
3.3 Tissue residency, migration and circulation of ILCs  
 
Helper ILCs are tissue resident cells, while NK cells continuously circulate in the blood 
stream and lymphatic system. In humans, NK cells comprise around 15% of the total 
lymphocyte population that circulate in the blood, though only a minute fraction of helper ILCs 
can be found in the blood of healthy subjects (Brunotte-Strecker and Infante-Duarte 
unpublished data). NK cells are enriched in the red pulp of the spleen and are able to migrate 
to lymph nodes and sites of infection. Most of the initial studies on NK cells were performed 
using NK cells derived from mouse spleen. Splenic NK cells are therefore the prototypical NK 
cells, which are also called conventional NK (cNK) cells. Subsequently, tissue-resident NK 
cells were described in thymus, liver, uterus and salivary glands (96–99). It was later 
recognized that most of this tissue-resident NK cells represent ILC1s (57,100). However, some 
organs maintain a great diversity of particular NK cell subsets that are difficult to classify within 
the ILC spectrum, like the uterine NK cells. Thus, uterine tissue harbors Eomes−CD49a+ 
ILC1s, Eomes+CD49a− cNK cells and Eomes+CD49a+ tissue resident NK cells (99). Each 
subset seems to have a specialized function during reproductive life. Tissue resident NK cells 
expand during early gestation while cNK cells expand during late pregnancy. Interestingly, 
ILC1s expand during second pregnancies suggesting a potential memory role of this subset 
(101). 
Furthermore, properties that many tissue-resident NK cells have in common and that 
makes them hard to classify into the ILC1 subset is their cytotoxicity potential (61,96) and their 
development independent of the transcription factor Nfil3 (96,98,102,103). Therefore, these 
cells have also been called cytolitic or killer ILC1s (70,71). The dependency on Nfil3 was tested 
using the mouse deficient in this transcription factor. However, it has been argued that the 
impact of this transcription factor in the Nfil3-deficient mouse is affected by the environment 
(like ongoing inflammation or variable housing conditions). Thus the dependence on Nfil3 is 
most likely insufficient to define a cell lineage, especially in endocrine organs where the tissue 
microenvironment is enriched with factors not present in other tissues (57,104). 
Tissue residency of ILCs has been demonstrated in parabiosis experiments. In the 
parabiotic mouse model, the skin of two mice are stitched together in the flanks; the wound 
healing process join the bloodstream of the animals through capillary networks, which results 
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in the two mice sharing a common bloodstream. By joining mice that express different alleles 
of CD45 (CD45.1 vs CD45.2), the presence of cells originating from one mice can be detected 
in the tissue of the conjoined mice. In this way, it was shown that NK cells recirculate, as their 
composition in diverse organs of the parabiont was chimeric (that is, contained both CD45.1+ 
and CD45.2+ NK cells). On the other hand, ILC composition displayed no chimerism as more 
than 95% of them expressed the host CD45 allele, thus demonstrating that ILCs do not 
recirculate. (105). An exception to this is the ILC2s, it was recently shown that upon helminth 
infection, inflammatory ILC2s are able to circulate and migrate to diverse organs (106).  
 
3.3.1 Chemokines and adhesion molecules 
  
Chemokines are a large family of small proteins that mediate chemotaxis of nearby cells. 
Their receptors are composed by a superfamily of G-protein-coupled seven-transmembrane 
receptors named according to the number of aminoacids between their conserved cysteine 
residues; namely the C, CC, CXC and CX3C families. About 50 chemokines and 20 functional 
receptors are known. A given receptor usually interacts with more than one chemokine and 
several chemokines can bind to more than one receptor (107), creating a very complex network 
in which redundancy may exist. However, detailed investigations have revealed that many axis 
in this network are highly fined-tuned. For example, the different ligands of CXCR3 – CXCL9, 
CXCL10 and CXCL11 – bind to their receptor with different affinities eliciting differential cell 
signalling responses (108). 
Cell adhesion molecules (CAMs) include many families of transmembrane receptors that 
interact with the cytoskeleton in their intracellular domain and with components of the 
extracellular matrix (ECM) or other adhesion molecules in its extracellular domain. Among the 
many CAMs that mediate lymphocyte migration and retention are the integrins. Integrins are 
heterodimers composed by an alpha chain and a beta chain. Mammals have 24 alpha subunits 
and 9 beta subunits (109). As mentioned above, ILC1s express the apha-1 integrin CD49a, 
this subunit dimerizes with beta-1 integrin subunit to form a complex that binds to collagen and 
laminin present in the ECM of the tissues (110). Intraepithelial ILC1s express the integrin 
alpha-E CD103, this subunit forms a complex with beta-7 integrin that is able to bind to E-
cadherin found in epithelial cells (111).  
An interplay between the expression of chemokine receptors and adhesion molecules 
determine the migratory potential of a lymphocyte. The expression of such receptors and 
molecules is highly dynamic in the lymphocyte lifespan and is determined by developmental 
and environmental cues, such as inflammation. During steady state, tissues constitutively 
express chemokine ligands that act as “homing” signals to attract lymphocytes, like the ligands 
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of CCR7 – CCL19 and CCL21 – that are abundant in secondary lymphoid organs (112,113). 
During inflammation, a different set of chemokine ligands might be upregulated to attract a 
diverse range of immune cells. Specialized cell subsets can be recognized by their chemokine 
receptor expression. In this line, we showed that CX3CR1 is expressed in mature NK cells in 
both humans and mice, and that it mediates the migration of mature NK cells into the inflamed 
CNS (114,115). In the case of ILC1s, the expression of CXCR6 and sometimes CXCR3 have 
been described as a distinctive feature of this ILC subset. CXCR6 is associated with homing 
to the liver as its ligand, CXCL16, is constitutively expressed in the liver sinusoidal endothelium 
(116). CXCR6 has been associated with the homeostasis and function of liver memory 
ILC1s/NK cells (117). CXCR3 ligands are induced in the tissues during inflammation by IFN-γ 
(118,119). This mechanism is crucial for the mobilization of activated and memory T cells to 
sites of inflammation (120,121). The role of this cytokine in ILC1 and NK cell recruitment has 
been poorly studied.  
Signalling through chemokine receptors can modulate other functions than chemotaxis 
and activate differential signalling cascades depending on the ligand. This was shown in 
murine CD4+CXCR3+ T cells, in which CXCR3 signalling induced by the ligands CXCL9/10 
promoted a polarization to TH1/17 cells, while the activation with CXCL11 promoted a Th2/Tr1 
polarization (122). It is unclear whether this biased signalling is present in CXCR3-expressing 
group 1 ILCs.  
Chemotactic molecules present in the bloodstream induce the egress of lymphocytes 
expressing their respective receptors from the tissues. In particular, a gradient of sphingosine-
1-phosphate (S1P), a signalling sphingolipid that binds to its G protein-coupled receptors 
S1P1-S1P5, is present in the blood provoking the lymphocytes to egress tissues and enter the 
circulation. The lectin CD69 inhibits this process by forming a complex with S1P1 in the cells, 
provoking its internalization and destruction (123–125). CD69 is also used as an early 
activation marker in lymphocytes. In line with this, ILC1s constitutively express CD69, while 
NK cells upregulate this molecule only after activation.  
 
3.3.2 Homing of immune cells into the healthy and inflamed CNS  
 
The central nervous system is considered to be an immune privileged organ. This term 
refers to an organ that has a limited capacity to mount an immune response in the presence 
of an antigen. This concept was demonstrated in the middle of the 20th century with tissue 
grafts experiments. Tissue grafts are normally recognized as foreign and rejected by the 
immune system. A tissue graft implanted into the brain parenchyma is tolerated and able to 
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survive for a long time without rejection (126,127). The lack of a lymphatic system in the brain 
parenchyma and the particularities of the blood brain barrier (BBB) led to the hypothesis that 
the immune system had no access to the CNS parenchyma. In contrast to the blood vessels 
in the peripheral organs, the endothelial cells that form the blood vessels in the CNS are joined 
by tight junctions, rendering them almost impermeable to cells and solutes. The endothelial 
cells of the BBB are surrounded by pericytes, a basal membrane and astrocytic end-feet, which 
serve as support and provision of regulatory factors (128). The brain parenchyma is 
surrounded by cerebrospinal fluid (CSF) and three layers of meninges: dura mater, arachnoid 
mater and pia mater. The pia mater is a one-layer permeable membrane that is directly coating 
the brain parenchyma and associated blood vessels. Beneath the pia, the glia limitants, 
composed by basal membrane and astrocytic end-feet, represent another border to the brain 
parenchyma. Between the pia and the arachnoides, a subarachnoid space is formed where 
CSF flows. The arachnoid mater is adjacent to the dura mater. The dura mater is a fibrous 
membrane that contains arteries, veins and lymphatics, all of which are fenestrated and allow 
the transport of cells and solutes. The arachnoid matter is impermeable thanks to its tight 
junctions, representing the real CSF-blood barrier that separates the CSF bathed brain 
parenchyma from the contents of the dural lymphatics and vessels (129). The CSF is 
constantly produced in the choroid plexus (CP) in the brain ventricles. The choroid plexus 
consists of a layer of epithelial cells surrounding a core of capillaries and connective tissue, 
also called stroma. The endothelial cells of the capillaries of the CP are fenestrated allowing 
the entry of immune cells into the CSF. However, the epithelial cells of the CP contain tight 
junctions forming a barrier between the CSF and the blood (blood-CSF barrier). This complex 
architecture makes the CNS a very difficult place to access. However, it is currently accepted 
that immune surveillance – a continuous process whereby the peripheral immune system is 
able to monitor an organ for signs of infection or tissue damage – occurs in the CNS and that 
it is essential to maintain CNS homeostasis (130–132). Indeed, one of the early experiments 
on graft rejection showed that a condition to elicit graft rejection in the brain was to first expose 
the animals to the graft antigen in the periphery (126). This indicates that the T cells that are 
activated in the periphery by a CNS antigen are able to reach the brain and mount an immune 
response. This is precisely the principle of the animal model for autoimmune inflammation, the 
experimental autoimmune encephalomyelitis (EAE), which will be further described in the 
following section. This model has been instrumental for the understanding of the recruitment 
of immune cells to the CNS. 
The recently rediscovered dural lymphatics were shown to have a connection with the 
deep cervical lymph nodes, which enables the passage of cells and macromolecules from the 
CNS into the periphery (2). In addition, drainage of antigens present in the CSF can reach the 
nasal and deep cervical lymph nodes by leaking through the cribriform plate into the nasal 
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mucosa (133,134). CSF can also exit through the arachnoid villi and reach the venous system 
in dural venous sinuses (135). Immune cells in turn, can enter the CNS through the choroid 
plexus, leptomeninges (arachnoid plus pia matter) and the perivascular spaces. However, the 
breaching of the above mentioned barriers that protect the brain parenchyma needs the 
inflammation-induced release of several factors including ECM remodelling proteases such as 
matrix metalloproteinases (MMPs), cytokines, chemokines and adhesion molecules (136,137). 
Chemokines play important roles in mediating the localization and barrier crossing of immune 
cells into the CNS. For example, chemokines like CXCL12 and the CXCR3 ligands are 
expressed in perivascular spaces and limit the localization of immune infiltrates into this space 
limiting inflammation in EAE (138,139). We showed that the expression of CX3CR1 in mature 
NK cells is needed for the infiltration of this protective subset into the inflamed brain (115). 
 
Under steady state, immune cells are found in CNS compartments. The CP stroma, the 
subarachnoid space and the lining of the brain ventricles contain dendritic cells and 
macrophages that are able to present antigen to T cells (140–142). Interestingly, permeability 
of the CP epithelial layer was shown to be regulated by IFN-γ derived from resident effector 
memory T cells (defined as CD4+CD44highCD62Llow) (143,144). Importantly, the possible role 
of IFN-γ-secreting group 1 ILCs in regulating CP permeability has not been explored.  
In humans, the CSF of individuals with non-inflammatory diseases is found to contain 
central memory T cells (defined as CD4+CD45RA-CD27+CD69+) (145) and immature 
CD56bright NK cells (146). The brain parenchyma is enriched with its own immune system cells, 
the microglia. Microglia colonize the CNS in early stages of embryonic development from 
primitive yolk sac macrophages (147). They serve varied functions during CNS development 
and regulate homeostasis in the adult brain (148). Microglia can be distinguished from the 
peripheral derived immune cells by a lower density of CD45 expression and a high expression 
of CD11b and CX3CR1 (149).  
In addition to microglia, other immune cells are detected in the healthy CNS. In our lab, 
we systematically detect CD3+, CD11b+ and NK1.1+ cells in thoroughly perfused CNS of 
healthy murine from diverse strains. Other groups have reported the presence of 
NK1.1+NKp46+ or NK1.1+CD49b+ cells in the healthy CNS (150,151). However, a detailed 
investigation of the composition of tissue resident ILCs within the CNS compartments is 
completely lacking. Given the obligate tissue resident nature of ILC1s and its role in tissue 
homeostasis and early response to inflammation demonstrated in other organs, it is of great 
interest to characterize the group 1 ILCs that reside in the CNS. 
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Next, multiple sclerosis, the major autoimmune disorder that involves a dysregulation in 
the homeostasis of CNS immunity will be introduced. Followed by the description of its animal 
model, EAE, and the implications of group 1 ILCs in MS and EAE etiology.  
 
 
3.4 Multiple sclerosis 
 
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system 
characterized by demyelination and subsequent axonal degeneration. MS is the leading cause 
of long-term disability in young adults (152). In Germany alone, nearly 200 000 people have 
been diagnosed with MS (153). MS is three times more common in women than in men and 
affects more people that live above 40° latitude and those from Caucasian origin (152). These 
incidence data suggest a complex interplay between genes, hormones and environment that 
is still subject of thorough investigations. Demyelinating lesions in MS appear in the brain, optic 
nerve and spinal cord, causing a broad spectrum of symptoms that depend on the location of 
the lesion. The most common symptoms are visual, motor, sensory and autonomic deficits, 
but speech, cognitive and emotional functions can also be affected (154). 
MS most frequently follows a relapsing-remitting (RRMS) course which is characterized 
by defined “attacks” of worsening neurological functions followed by “remissions” that involve 
partial or complete recovery. A lower number of patients are diagnosed with primary-
progressive MS (PPMS) where a slow progressive worsening of neurological function occurs 
with no distinct relapses or remissions. In addition, about 65% of patients that suffer from 
RRMS develop a secondary-progressive (SPMS) course after 10-25 years of the disease 
(154). 
The etiology of MS is not completely understood. Genetic factors that increase the 
susceptibility for MS are associated with some allelic variants of the human leukocyte antigen 
(HLA) system (the human MHC proteins), particularly HLA DR15 (155). In addition, genome 
wide studies have associated single-nucleotide polymorphisms (SNPs) of important immune 
regulators like IL-12RA and IL-7RA as heritable risk factors for MS (156,157). However, the 
probability that both identical twins are affected by the disease is only 25% (158–160) 
indicating that environmental factors play a significant role in initiating the disease. A protective 
role of vitamin D has been proposed since MS patients often present vitamin D deficiency and 
incidence data worldwide correlate with regions of low UVB ray exposure, which is essential 
for the vitamin D conversion in the skin. Vitamin D is an important immune modulator, and the 
supplementation of MS patients may have potential therapeutic effects (161). 
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Infections are possible triggers of MS. Epstein-Barr virus (EBV) infection in young adults 
increases the susceptibility to develop MS (162). While the reason of this correlation is still 
unclear, the mechanism probably involves EBV infected memory B cells (163,164). In addition, 
relapses are associated with common viral infections (165). The proposed mechanism by 
which an infection can trigger MS involves a process called “molecular mimicry”. This process 
occurs when structural motifs of a virus resemble molecules of the host, thus, the immune 
system attacks self-structures that are confused with foreign antigens. Another mechanism is 
the “bystander activation”, where the inflammatory response provoked by the infection causes 
the activation of pre-existent autoreactive T cells or reveals hidden autoantigens (also called 
epitope or antigen spreading) (166).  
In the last decade, the role of the gut microbiome as important regulator of health has 
emerged. In line with this, investigations of gut microbiome of MS patients have shown that 
MS patients exhibit an altered gut microbial composition (known as dysbiosis) compared with 
healthy controls. These studies suggest that certain bacterial compositions have an anti-
inflammatory role that contribute to limit autoimmunity (167).  
Regardless of the factor that may trigger the disease, MS is considered to be T cell 
mediated. Autoreactive CD4+ T cells, activated by a CNS antigen (which still remains 
unknown) by local or peripheral APCs, migrate through the (perhaps already disrupted) BBB 
into the brain. There, they release cytokines, initiating an inflammatory response that activates 
local microglia and recruit other immune cells such as cytotoxic CD8+ T cells, B cells and 
macrophages. Although remyelination occurs, and it is associated with remissions, defective 
immune regulation as well as extended oligodendrocyte damage makes a complete 
remyelination a difficult task. As a consequence, the exposed axons degenerate leading to 
neuronal loss and permanent disability. Both Th1 (IFN-γ, TNF-α producing) and Th17 (IL-17 
producing) responses, and a low suppressive activity of regulatory T cells (Tregs) have been 
associated with the disease (168). In addition, a central role of autoimmune B cells is also 
emerging in the field (169,170).  
Magnetic resonance imaging (MRI) is the most sensitive tool to diagnose MS. With the 
use of a contrast agent containing the metal Gadolinium, white matter lesions in the brain and 
spinal cord can be identified. In addition to MRI, laboratory methods such as the analysis of 
inflammatory markers in the CSF are useful to complete the diagnosis (171). The first acute 
episode involving one or more focal demyelination sites is called clinically isolated syndrome 
(CIS), about 60% of CIS patients develop MS over the next 20 years (172). The expanded 
disability status scale (EDSS) proposed by Kurtzke in 1983 is currently used to evaluate the 
degree of neurological impairment in MS (173). The scale goes from 0 to 10, where 0 is no 
disability and 10 is death due to MS. The patient is scored after neurological testing of different 
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functional systems. MS patients with scores 1 to 4.5 are fully ambulant while the patients with 
score 5 to 9.5 have increasing degrees of disabilities that impairs daily activities. 
Although MS has no cure, great advance has been made in the last decades in the 
development of disease modifying therapies that can substantially reduce the impact of MS on 
the lives of many patients. Many of those have been developed thanks to research with the 
EAE animal model of the disease, which has been instrumental to understand the disease 
mechanisms of neuroinflammation and the importance of immune cells in regulating CNS 
homeostasis.  
 
3.4.1 Experimental autoimmune encephalomyelitis as the mouse model of MS 
 
Not a single animal model can capture the heterogeneity and spectrum of MS. However, 
several animal models have been established that recapitulate certain aspects of human MS. 
In particular, the experimental autoimmune encephalomyelitis model has brought important 
insights into the pathogenic mechanisms of MS and contributed in the development and testing 
of novel therapeutic strategies.  
EAE is induced by immunizing laboratory animals with myelin antigens and potent 
coadjuvants, which then develop an inflammatory disease of the CNS with various degrees of 
demyelination that correlate with clinical symptoms characterized by ascending paralysis. It 
was already noticed at the beginning of the 20th century that the anti-rabies vaccination could 
produce neuroparalitic complications in some subjects (174). The attenuated virus used in this 
vaccine was isolated from neural tissue cultures. Presumably, contamination of nervous tissue 
in the vaccine could have led to an autoimmune attack to the CNS manifested as an acute 
disseminated encephalomyelitis (175). Based on these observations, the first attempts to 
produce an experimental autoimmune encephalomyelitis were done 1933 in monkeys, using 
intramuscular injections of rabbit brain extract emulsions (176). The protocol was subsequently 
refined and applied to many other species including rabbits, guinea pigs, rats and mice. The 
mice model is currently the most popular model, and the availability of different transgenic and 
knock-out mice makes it a useful tool to investigate the role of a specific gene, protein or cell 
type in the disease pathogenesis.  
An active immunization, or a passive adoptive cell transfer strategy can be used to 
induce EAE in mice. For the active strategy, depending on the mouse strain, different myelin 
peptides are used in the immunization protocol and different disease courses are achieved. 
When using the C57BL/6 mouse strain, a highly immunogenic (immunodominant) region of the 
myelin oligodendrocyte glycoprotein (MOG) is used to immunize the mice, usually the MOG35-
   33 
55 peptide. The peptide is prepared as an emulsion together with complete Freund’s adjuvant 
that contains inactivated mycobacterium, which serves as a massive immune stimulant, and 
applied subcutaneously usually in flanks of the mouse. Injections of pertussis toxin are 
performed on the day of immunization and 48 hours after, which are necessary to augment the 
sensitization process. After 10 to 15 days, the mice develop a monophasic chronic EAE 
disease course, in which the animals may recover after a phase of clinical disease but do not 
present relapses. Similarly, the SJL mice are immunized with a proteolipid protein (PLP) 
antigen, usually PLP139-151, to elicit an EAE with a relapsing remitting disease course. Although 
in the active immunization model, the disease is mainly mediated by autoreactive CD4+ T cells, 
the model has also allowed to discern the contribution of other immune cells to the 
pathogenesis of the disease, thanks largely to the genetic models available in the C57BL/6 
background (177,178). 
In the passive strategy, encephalytogenic T cells are obtained from the lymph nodes of 
an actively immunized mice. The cells are reactivated and expanded with the myelin peptide 
and APCs in vitro and then intravenously transferred into the recipient mice, usually a SJL 
mice that develops in a few days a relapsing remitting form of EAE. The passive EAE strategy 
has been useful to demonstrate the contribution of each CD4+ Th1 and Th17 cell subset in the 
development of the disease, to study the T-cell mediated immune surveillance and 
inflammatory tissue damage (175,179).  
Overall, the EAE model is useful to study mechanisms of autoimmunity and 
neuroinflammation, but it does not recapitulate many aspects of MS. For example, 
inflammation and demyelination in active EAE is more common in the spinal cord, while in MS 
it is almost restricted to the brain. MS progression is difficult to study in EAE and the cell 
component is largely skewed to CD4+ T cells, while in MS, the contribution of other immune 
cells to disease pathology is also crucial (180). Therefore, toxic-induced models of 
demyelination such as the cuprizone model, which triggers apoptosis in oligodendrocytes and 
induces demyelination through mechanisms of oxidative injury, are more useful to study the 
process of de- and re-myelination (181). 
 
3.4.2 The role of group 1 ILCs in MS and EAE 
 
Early investigations of the implication of NK cell in MS revealed that MS patients have 
an impaired effector NK cell function. In specific, cytotoxicity of peripheral blood-derived NK 
cells against tumoral cells in in vitro assays was diminished in MS patients compared to healthy 
controls (182–184). Furthermore, longitudinal studies in RRMS patients showed that decline 
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in NK cell cytotoxic function preceded the appearance of new or enlarged of MRI lesions 
(185,186) and clinical relapses (187). Moreover, it was also found that the CD56bright NK cell 
subset presented a reduced capability to produce IFN-γ and to proliferate following cytokine 
activation (188). All these data suggested a protective role of NK cells in MS with a mechanism 
that is subset-specific. Indeed, our research group reported that CD56dim from MS patients had 
a reduced CX3CR1 expression, and that stable but not active MS patients had an elevated 
frequency of circulating CD56bright NK cells (189). In addition, we showed that the overall 
frequency of NK cells in CSF – which is enriched with CD56bright cells – is reduced in MS 
patients compared to patients of non-inflammatory neurological diseases (146). Interestingly, 
during pregnancy, MS activity is reduced while the proportion of circulating CD56bright NK cells 
augments (190). Thus, the CD56bright seems to have a protective immunomodulatory role in 
MS. In line with this, some therapies for MS like IFN-β (191) and daclizumab (192) results in 
an expansion of CD56bright NK cells that is accompanied by a reduction of disease activity. The 
mechanisms behind a protective role of NK cells in autoimmunity lie in the fact that NK cells 
can kill other immune cells, which becomes beneficial when those cells are autoreactive T 
cells. For example, it was shown that MS patients have a reduced expression of the co-
activatory receptor DNAM-1 on both CD56bright and CD56dim NK cells. In addition, their antigen 
activated CD4+ T cells have a reduced expression of DNAM-1 ligand CD155. This provoked 
a decreased interaction of NK cells and T cells that resulted in a decreased NK cells cytolitic 
activity against the activated T cell. Interestingly, daclizumab treatment (an antibody that 
targets the IL-2R) restored that interaction by inducing an increase in CD155 expression on T 
cells and expanding NK cells (193). Similarly, it was shown that T cells from MS patients have 
an increased expression of HLA-E, which acts as a ligand of the inhibitory NK cell receptor 
NKG2A, resulting in a decreased ability of NK cells to suppress autologous CD4+T cell 
proliferation (194). Furthermore, MS treatments that employ monoclonal antibodies such as 
Alemtuzumab (which targets CD52 on T and B cells) and Rituximab (which targets CD20 on 
B cells) might work by inducing an antibody-dependent cell-mediated cytotoxicity by NK cells 
(195,196). However, NK cell cytotoxicity is a double-edged sword that could also have a tissue 
damaging role in the CNS during MS, as it has been shown in some EAE studies.  
Investigations of the role of NK cells in the EAE model have at first sight drawn seemingly 
contradictory results. On one hand, detrimental roles of NK cells in EAE development were 
reported. IL-18 knockout mice, which have reduced NK cell numbers, are resistant to MOG-
induced EAE. EAE could be established by treating the mice with IL-18, but this was not 
possible in NK cell depleted mice, suggesting a role of NK cells in the establishment of 
autoimmunity (197). In another study, the depletion of NK cells before MOG immunization with 
anti-NK1.1 or asialo GM1 treatment, decreased both the frequency and the extent of disease 
compared with EAE control mice (198). On the other hand, protective roles of NK cells have 
   35 
been reported. For example, the same anti-NK1.1 depleting treatment was shown to induce a 
more severe EAE disease in both MOG-induced  (199), and PLP-induced model (200). 
Moreover, the expansion of NK cells with anti-IL-2Ra antibody resulted in a less severe EAE 
in SJL mice together with a reduction of the activity of Th17 in the CNS (201). Like in MS, one 
of the mechanism proposed by which NK cells limit autoimmunity in the EAE model is by lysing 
autoreactive T cells. The interaction of the inhibitory receptor NKG2A with the ligand Qa-1 in 
T cells (mouse homolog of human HLA-E), has been shown as a mechanism by which T cells 
escape NK-mediated lysis. Thus, the blockage of this interaction with an antibody treatment 
resulted in an enhanced elimination of autoreactive T cells and decreased EAE disease course 
(202,203). 
We and others have shown that the presence of NK cells in the CNS during 
neuroinflammation has a protective role. Mice deficient for the chemokine receptor CX3CR1 
(CX3CR1-/-) show a defective recruitment of NK cells into the CNS and an enhanced EAE 
severity (204). We showed using the same mice, that mature CD11b NK cells was the subset 
that failed to migrate to the CNS during neuroinflammation, and that this subset had a more 
potent response against autoreactive T cells (115). This is in line with another report that 
showed enhanced Th17 responses in the CNS of CX3CR1-/- mice (205). A detrimental role of 
NK cells present in the CNS was also reported, specifically in chronic stages of MOG-induced 
EAE (206). Liu and colleagues showed that NK cells accumulated in the subventricular zone 
(SVZ) in proximity to neural stem cells (NSC) during neuroinflammation. NSC sustained NK 
cells by secreting IL-15 and the presence of NK cells during chronic neuroinflammation 
resulted in the lysis of NSC limiting, thus, oligodendrogenesis and recovery. In sum, these data 
indicate that the role of NK cells in autoimmunity is largely dependent on the subset and 
disease stage investigated.  
The role of ILC1s in MS has not been explored yet. The absence of ILC1s in the 
circulation and the low availability of tissue from patients limits the study of the role ILC1s in 
human disease. It is also important to note, that the above-mentioned investigations of NK 
cells in the EAE model have overseen the implication of ILC1s, either because ILCs were just 
recently formally described or due to the lack of tools to specifically target ILC1s. As both NK 
cells and ILC1s express NK1.1, many of the studies might have inadvertently targeted ILC1s; 
for example, when using anti-NK1.1 antibody treatments (198–200) or when visualizing NK1.1 
cells that express a fluorescent reporter (206). 
Few studies have addressed the role of ILCs in EAE. Using the EAE model induced by 
the adoptive transfer of Th17 cells, Kwong and colleagues showed that NKp46+ ILCs 
accumulate in the meninges and that there they promote a microenvironment that allows Th17 
reactivation and parenchymal invasion. A specific role of ILC1s and NCR+ ILC3s was 
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suggested, as the specific deletion of Tbet in NKp46 expressing cells (using the Tbx21f/f 
NKp46-Cre+ mice) resulted in a less severe disease, while the use of a NK cell-specific deletion 
(using the Eomesf/f NKp46-Cre+ mice) did not affected the outcome of the disease (207).  
In sum, NK cells and ILC1s have important and differential roles in modulating 
neuroinflammation. However, a thorough description of the phenotypic and functional 
characteristics of the group 1 ILCs that reside in the CNS is completely lacking. Therefore, the 
present doctoral thesis tackles this problem by providing a resource to allow the unambiguous 
identification of NK cells and ILC1s inside the murine CNS. 
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4 Aims of the Thesis 
  
The identification of the mechanisms that mediate the trafficking of immune cells during 
homeostasis and inflammation has led to the development of successful treatments for 
autoimmune diseases such as MS. In this line, the trafficking of NK cells into the CNS deserves 
further investigation. In humans, multiple evidence suggest that NK cells have a beneficial, 
disease-limiting role in MS. In mice, the trafficking of mature CX3CR1+ NK cells into the CNS 
was shown to be beneficial in the EAE model of MS. However, immature NK cells are also 
present in the inflamed CNS. The chemokine receptors that mediate their migration to the CNS 
remain unclear. In addition, NK cells (defined as CD3-NK1.1+ cells) are already present in the 
CNS of healthy mice, which suggest a long-term tissue residency of these cells. Contrary to 
NK cells, helper ILCs reside in the tissues and do not recirculate. Taking into account the 
phenotypical similarities of NK cells and ILC1s, it is possible that some of the CD3-NK1.1+ 
cells present in the CNS constitute bona fide ILC1s.  
 
Therefore, the overall aim of this thesis is to investigate into these two hypotheses: 
1) The CNS immature NK cells migrate from the periphery using a specific chemokine receptor. 
2) The CNS immature NK cells, or other subsets within the CD3-NK1.1- cells, constitute 
resident ILC1s.  
 
The specific questions of these two hypotheses were addressed using the murine system 
and the MOG-induced active EAE model as a paradigm of CNS autoimmune inflammation.  
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5 Materials and Methods 
 
5.1 Laboratory materials  
 
5.1.1 Buffers, solutions and cell culture media 
 
Solution Components Company 
 
Phosphate buffered saline 
(PBS) 
 
 
 
 
 
Complete medium  
 
 
 
 
 
 
 
Wash medium 
 
 
 
 
 
FACS buffer 
 
 
 
MACS buffer 
 
 
 
137 mM NaCl 
2.7 mM KCl 
1.5 mM KH2PO4 
8.1 mM Na2HPO4 
pH 7.2 
or purchased from Gibco® 
 
RPMI-1640 
10% Fetal calf serum (FCS) 
100 U/ml penicillin  
100 µg/ml streptomycin 
1% Hepes 1M 
2 mM L-glutamin  
50 µM β-mercaptoethanol 
 
RPMI-1640 
5% FCS 
100 U/ml penicillin  
100 µg/ml streptomycin 
1% Hepes 1M 
 
PBS 
0.5% bovine serum albumin 
(BSA) 
 
PBS 
0.5% BSA 
2 mM EDTA 
 
Merck Millipore, Germany 
Carl Roth, Germany 
Merck Millipore, Germany 
Sigma-Aldrich, Germany 
 
Thermo Fisher, USA 
 
Gibco® Thermo Fisher 
Sigma-Aldrich 
Biochrom, Merck Milipore 
Biochrom, Merck Milipore 
Gibco® Thermo Fisher 
Gibco® Thermo Fisher 
Sigma-Aldrich 
 
Gibco® Thermo Fisher 
Sigma-Aldrich 
Biochrom, Merck Milipore 
Biochrom, Merck Milipore 
Gibco® Thermo Fisher 
 
 
Serva, Germany 
 
 
 
Serva 
Sigma-Aldrich 
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Cell fixing solution 
 
 
Saponin solution  
 
 
Red blood cell (RBC) lysis 
buffer  
 
 
 
 
MB solution 
 
 
 
 
37% Percoll® solution for 
CNS cell isolation density 
gradient 
 
37.5% Percoll® solution for 
liver cell isolation density 
gradient 
 
Meninges digestion medium 
 
 
 
 
Anaesthetic  
 
 
 
Trypan Blue solution 
 
 
PBS 
4% paraformaldehyde (PFA) 
final concentration 2% 
FACS buffer 
0.5 % Saponin 
 
distilled water 
150 mM KHCO3  
10 mM NH4Cl 
0.1 mM Na2EDTA 
pH 7.2 to 7.4 
 
132 ml water 
45 ml PBS 10X 
3 ml 0.6N HCl 
pH 7 to 7.2 
 
Percoll® pH 8.5-9-5 
MB solution  
 
 
Percoll® pH 8.5-9-5 
MB solution 
2mM EDTA 
 
Complete medium 
2 mg/ml DNAse 
2.8 mg/ml Collagenase type 
VIII 
 
415 mg/kg Ketamin 
9.7 mg/kg Xylazine  
in 0.9% NaCl solution 
 
PBS 
0.4% (w/v) trypan blue 
 
 
Carl Roth, Germany  
 
 
Carl Roth 
 
 
Merck Millipore 
Carl Roth 
Sigma-Aldrich 
 
 
 
Sigma-Aldrich 
Carl Roth 
 
 
Sigma-Aldrich 
 
 
 
Sigma-Aldrich 
 
Sigma-Aldrich 
 
 
Sigma-Aldrich 
Sigma-Aldrich 
 
 
Iniesa Arzemittel, Germany 
CP Pharma, Germany 
 
 
 
Sigma-Aldrich 
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5.1.2 Additional chemicals and reagents 
 
Chemical / Reagent Company 
 
Brefeldine A 
Complete Freund’s adjuvant (CFA) 
Dimethylsulfoxide (DMSO) 
Ethanol 
Histopaque® 
Ionomycin 
IL-12, recombinant mouse 
IL-15, recombinant mouse 
IL-18, recombinant mouse 
InVivoMab Anti-CXCR3 (clone CXCR3-
173) 
InVivoMab polyclonal Armenian hamster 
IgG 
Mycobacterium tuberculosis H37 RA 
Myelin oligodendrocyte glycoprotein 35-
55 (MOG35-55) 
Pertussis toxin (PTX) 
 
Biolegend, California, USA 
Difco Laboratories, Detroit, USA 
Sigma-Adlrich 
Merck Millipore 
Sigma-Adlrich 
Sigma-Adlrich 
R&D Systems, Minneapolis, USA 
R&D Systems 
R&D Systems 
BioXcell, West Lebanon, USA  
BioXcell 
Difco Microbiology, Lawrence, USA 
Pepceuticals Ltd., Leicester, UK 
 
Sigma-Aldrich 
 
5.1.3 Kits  
 
Kit Company 
 
True-NuclearTM Transcriotion Factor Buffer Set  
FoxP3 Transcription Factor Staining Buffer Set 
NK Cell Isolation Kit II, mouse  
 
Biolegend, California, USA 
eBioscience, Thermo Fisher  
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
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5.1.4 Devices 
 
Device Company 
 
Balance, Kern EW 820-2NM Benchtop 
Centrifuge 
Cell Incubator 
Eppendorf Centrifuge 5417R  
Eppendorf Centrifuge 5810R  
GFL WaterBath 
HeraCell Incubator 
HeraeBus Multifuge 3SR+ 
Laminar flow hood HeraSafe 
LSR FortessaTM 
MACS Separators and stand 
Magnetic stirrer 
Megafuge 1.0  
Neubauer counting chamber 
pH Meter 
Pipettes (2, 10, 20, 200 and 1000 μl) 
Pipetus® 
Rotamax 120 Orbital Shaker 
Thermomixer Compact 
Timer 
Vacuum Pump 
Vortex Genie 2 
Wilovert S Inverted Microscope 
 
Kern & Sohn GmbH, Balingen Germany 
NeoLab, Heidelberg, Germany 
Binder GmbH, Tuttlingen, Germany 
Eppendorf AG, Hamburg, Germany 
Eppendorf AG, Hamburg, Germany 
GFL, Burgwedel, Germany 
Heraeus, Hanau, Germany 
Thermo Fisher Scientific, Waltham, USA 
Heraeus, Hanau, Germany 
BD Pharmigen, Heidelberg, Germany 
Miltenyi Biotec, Bergisch Gladbach, Germany 
MLW RH3, Germany 
Thermo Fisher Scientific, Waltham, USA 
Brand GmbH & Co KG, Wertheim, Germany 
Schott Instruments GmbH, Mainz, Germany 
Eppendorf AG, Hamburg, Germany 
Hirschmann Laborgeräte, Eberstadt, Germany 
Heidolph Instruments, Schwabach, Germany 
Eppendorf AG, Hamburg, Germany 
Eppendorf AG, Hamburg, Germany 
KNF Neuberger Inc., Trenton, USA 
Scietific Industries Inc. Bohemia, USA 
Helmut Hund GmbH, Wetzlar, Germany  
 
5.1.5 Software 
 
Software Company 
 
BD FACSDivaTM 
FlowJo v10.4 
GraphPad Prism v8 
Mendeley® 
 
BD Bioscience, Heidelberg, Germany 
FlowJo LLC, Ashland, Oregon, USA 
GraphPad Software Inc., San Diego, USA 
Elsevier, Amsterdam, Netherlands 
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Microsoft Office 2016 Microsoft Corporation, Redmond, USA 
 
5.1.6 General consumables 
 
Consumable Company 
 
Cell strainers (75 and 100 µm pore size) 
Cellstar® serological pipettes 
 
Corning® 12, 24, 48 and 96 -well culture 
plates  
Corning® Petri dishes 
Dumont medical dissection instruments: 
forceps, scissors, spatula, scalpels, 
hemostats and pins  
Eppendorf tubes (0.5, 1.5 and 2 ml) 
FalconTM conical tubes (15 and 50 ml) 
FalconTM 5 ml round bottom tube with cell 
strainer cap  
MACS LS-Columns 
Micronic 1.10 ml tubes 
Parafilm 
Pipette tips (all sizes) 
Reaction vessels (glassware) 
 
Reaction vessels (plasticware) 
Serological pipettes 
Sterican® needles 
Syringes  
Transfer pipette  
TrueCountTM tubes 
Vasco® Nitril gloves 
 
 
 
 
 
BD Bioscience, Heidelberg, Germany 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Sigma-Aldrich, Schnelldorf, Germany 
 
Sigma-Aldrich, Schnelldorf, Germany 
Fine Science Tools GmbH, Heidelberg, 
Germany 
 
Eppendorf AG, Hamburg, Germany 
BD Bioscience, Heidelberg, Germany 
BD Bioscience, Heidelberg, Germany 
 
Miltenyi Biotec, Bergisch Gladbach, Germany 
Micronic, Lelystad, Netherlands 
American Can Company, Greenwich, USA 
Sarstedt AG & Co, Nümbrecht, Germany 
Schott AG and DURAN Group GMbH, Maiz 
Germany 
Vitlab, Großostheim, Germany 
BD Medical, Heidelberg, Germany 
B. Braun Melsungen AG, Hessen, Germany 
BD Bioscience, Heidelberg, Germany 
Sarstedt AG & Co, Nümbrecht, Germany 
BD Bioscience, Heidelberg, Germany 
B. Braun Melsungen AG, Hessen, Germany 
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5.2 Mice 
 
WT C57BL/6 mice were obtained from the Research Institute for Experimental 
Medicine (FEM) of the Charité (Berlin, Germany) and kept on a 12:12 h day:night cycle with 
ad libitum access to food and water. Rorc-CreTg; Rosa26RRFP/+ mice were provided by Chiara 
Romagnani. All animal experiments were approved by the regional animal study committee of 
Berlin (Landesamt für Gesundheit und Soziales) and performed in accordance to national and 
international guidelines. 
 
5.3 In vivo methods 
5.3.1 Induction and assessment of active EAE 
 
Active EAE was induced by immunizing each mouse subcutaneously with 250 µg of 
myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35-55) emulsified in complete Freund's 
adjuvant containing 800 μg of Mycobacterium tuberculosis H37Ra. Mice were immunized in 
the ventral flanks at four sites, in the axillar and inguinal areas, with a total volume of 50 µl per 
site. On the same day and after 48 hours, mice received an intraperitoneal injection of 200 µl 
of Pertussis toxin (PTX, 200 ng) dissolved in PBS. From the day 10 after immunization mice 
were weighted and examined daily for clinical symptoms and scored as follows: 0, no signs of 
clinical disease; 0.5, tail paresis; 1, tail plegia; 1.5, righting reflex weak; 2, hindlimb paresis; 
2.5, unilateral hindlimb plegia; 3, bilateral hindlimb plegia; 3.5, forelimb paresis; 4, forelimb 
plegia. Mice were euthanized when they reached a score of > 3 or loss more than 20% of their 
weight in comparison with mice of their same strain and age. Mice used were always females 
of 10 to 14 weeks of age and were housed for at least one week in the animal facility before 
starting the immunization protocol.    
 
5.3.2 Anti-CXCR3 antibody treatment 
 
Mice were divided into two groups of 5 mice and immunized as stated in the previous 
section. The mice were then intraperitoneally injected with 200 µg of anti-CXCR3 antibody or 
control IgG diluted in 100 µl of sterile PBS on day 0, 3, 6, 9 and 12 post-immunization. Mice 
were sacrificed at day 15 post-immunization, and the organs were processed for flow cytometry 
analysis. 
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5.3.3 Mouse perfusion and organ removal 
 
Mice were anesthetized with an intraperitoneal injection of a lethal dose of anesthetic 
containing xylazine and ketamine. When mice were deeply anesthetized, the pectoral cavity 
was opened starting from the abdominal cavity to expose the liver. The diaphragm was opened 
to expose the heart and the aorta was cut. The needle of a 26 G hypodermic lancet connected 
to a 12 cc syringe (20 ml) filled with PBS was inserted in the left ventricle of the heart, and the 
PBS was infused gently. In experiments where meninges and choroid plexus was collected, 
the mice were perfused with 60 ml of PBS by connecting the syringe to a 21 G butterfly needle 
that facilitates the exchange of syringes. After perfusion, the organs were removed. Only brains 
with no traces of blood were used in the experiments. 
 
5.4 Isolation of immune cells from mouse tissue 
 
All tissues were kept on ice (except blood) in tubes with medium until processed, no 
longer than one hour after dissection. The centrifugation steps were done at room temperature 
and without brake unless otherwise stated. The resulting cell solution was stored at 4°C until 
use for downstream applications, such as flow cytometry staining or in vitro culturing and 
assays.  
 
5.4.1 Blood 
 
Blood was collected from mice before perfusion after cutting the aorta. Blood was 
collected in tubes containing 500µl of 2 mM EDTA, mixed and kept at room temperature. Red 
blood cells were lysed with 10 ml of RBC lysis buffer for 10 minutes and centrifuged for 10 
minutes at 300 g. The pellet was washed with 10 ml of wash medium, after centrifuging an 
additional time at 500 g for 5 minutes, the cells were resuspended in 1 ml of complete medium 
or FACS buffer and counted.  
 
5.4.2 Spleen 
 
The spleen was collected after perfusion by locating it at the dorsal left side of the mouse 
behind the liver. Each individual spleen was mashed over a 100 µm cell strainer placed over 
a 50 ml tube with a syringe plug, continuously washing the cell strainer with wash medium. 
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The tube was filled up to 20 ml of medium and centrifuged at 500 g for 5 minutes at 4°C. The 
pellet was resuspended in 10 ml of RBC lysis buffer and incubated for 10 minutes. 5 ml of 
mouse medium was added and then centrifuged for 10 minutes at 300 g. After that, the pellet 
was washed with 15 ml of wash medium, centrifuged for 5 min at 500 g, 4°C and resuspended 
in 10 ml of FACS buffer of complete medium to be counted.  
In some experiments, the mononuclear cells of the spleen were isolated by gradient 
centrifugation. After mashing the spleen through the cell strainer and centrifuging, the cells 
were resuspended in 5 ml of complete medium, layered over 5 ml of Histopaque-1083 and 
centrifuged for 15 minutes at 800 g without brake. The layer of mononuclear cells was 
recovered between the medium and Histopaque layer and washed twice with complete 
medium.   
 
5.4.3 Lymph nodes  
 
The lymph nodes selected were the inguinal, axillary and brachial, unless stated 
otherwise. Lymph nodes were dissected after perfusion by separating the fur from the skin and 
locating them under the axillar area and over the microvasculature network in the inguinal area. 
The lymph nodes were mashed over a 100 µm cell strainer and washed with 10 ml of wash 
medium, after a centrifugation step at 500 g for 5 minutes at 4°C, the pellet was washed again 
with 10 ml of wash medium, centrifuged and resuspended in 5 ml of cmplete medium or FACS 
buffer for counting.  
 
5.4.4 Liver 
 
The liver was removed from the perfused mice and cleaned from the associated lymph 
nodes and gallbladder. The liver was then minced into small pieces and mashed through a 100 
µm cell strainer with a syringe plug over a 50 ml tube. The tube was filled up to 50 ml with 
complete medium and centrifuged for 1 min at 60 g, without brake. The supernatant was 
transferred to a new 50 ml tube and centrifuged at 480 g for 8 min. The pellet was resuspended 
in a 10 ml of a 37.5% Percoll solution diluted in in MB medium containing 2mM EDTA in a 15 
ml tube and centrifuged for 20 min at 850 g without brake. The resulting pellet was 
resuspended in 2ml of RBC lysis buffer and incubated for 5 minutes at room temperature. 
Afterwards, 5 ml of mouse medium was added and the solution was centrifuged at 480 g for 8 
minutes at 8°C. The pellet was resuspended in 3 ml FACS buffer or complete medium and 
counted.  
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5.4.5 Central nervous system 
 
The brain and the spinal cord was removed from the perfused mice. The tissue was 
mashed together through a 70 µm cell strainer washing extensively with complete medium 
until all tissue passed through the strainer. The solution was centrifuged at 400 g for 10 minutes 
at 4°C, the pellet was transferred to a 15 ml tube and resuspended in 6 ml of a 37% Percoll 
solution and centrifuged for 15 minutes at 2800 g without break. Afterwards, the myelin sheath 
that stayed in the upper layer of the Percoll solution was aspirated together with the Percoll. 
The pellet was recovered and washed two times in complete medium by centrifuging at 400 g 
for 10 min at 4°C. Between the first and the second wash, the cells were passed through a 30 
µm filter to remove any residual myelin or connective tissue. Finally, the cells were 
resuspended in 1 ml of FACS buffer or mouse medium and stored at 4°C until use.  
 
5.4.6 Meninges 
 
The dural meninges were removed from the skullcap of the perfused mouse by carefully 
opening the skull from the ventral side of the head. For that, the skin, muscles, eyes and 
connective tissue was removed from the head; the jaw was removed by severing the 
mandibular junction and the skull was cut open by inserting the scissors in the auditory meatus 
and carefully cutting around the skull. The ventral side of the skull was discarded and the 
exposed brain was carefully scooped out with the spatula and kept for choroid plexus isolation. 
The remaining skullcap was placed in a small Petry dish with cold PBS under a dissecting 
microscope. The dural meninges was scored around the edge of the skull with the tip of a 
Dumont #5 forceps, scrapping also the membrane attached to the sutures of the skull. In that 
way, it was possible to peel off the complete meningeal tissue. The collected tissue was 
resuspended in 500 µl of PBS with 2 mg/ml of DNAse I and 2.8 mg/ml of Collagenase type VIII 
and digested at 37°C in a thermomixer for 20 minutes, shaking at 400 rpm. The digested 
meninges were then homogenized by pipetting a few times with a 1 ml pipette and passed 
through a 70 µm cell strainer, the cell strained was extensively washed with complete medium, 
and the solution was then centrifuged at 400 g for 7 minutes at 4°C. Finally, the pellet was 
resuspended in 1 ml of FACS buffer. 
 
 
 
   47 
5.4.7 Choroid plexus 
 
The choroid plexus was removed by placing the perfused brain with the dorsal side facing 
up and the caudal side (cerebellum) facing towards the examiner in a Petry dish with cold 
mouse medium, under a dissecting microscope. The cerebellum was opened coronally in the 
junction with the cerebrum with a scalpel to access the fourth ventricle. The choroid plexus 
was removed from the cavity of the fourth ventricle with fine forceps and transferred to a tube 
with cold PBS. The choroid plexus from the third ventricle was removed by doing an incision 
with the scalpel starting at the confluence of the sinuses toward the sagittal sinus, trespassing 
the corpus callosum until the third ventricle was reached. The choroid plexus was then found 
attached to the upper wall of the ventricle. Finally, the lateral ventricles were exposed by cutting 
sagittaly with the scalpel about 4 mm parallel to the middle sinus on each side until the 
ventricles were exposed. The choroid plexuses were located hanging in the ventricle attached 
to the lateral walls and to the floor of the ventricles. The choroid plexus was then mashed 
through a 70 µm cell strainer extensively washing with PBS containing 5 mM EDTA. The 
solution was centrifuged 10 minutes at 600 g, at 4°C and the pellet resuspended in 1 ml of 
FACS buffer.   
 
5.5 Cell sorting methods 
5.5.1   Magnetic activated cell sorting  
 
Magnetic activated cell sorting (MACS) was used to separate NK cells from a preparation 
of mouse lymph nodes and/or splenocytes. The MACS technology consists on the use of a 
magnetic field to retain cells labeled with magnetic microbeads in a column attached to a 
magnet. The kit used in this study is based on negative selection strategy to isolate NK cells. 
Hereby, the non-target cells are magnetically labeled and retained in the column, while the 
unlabelled NK cells pass through the column and are collected. The protocol was followed 
according to the manufacturer’s instructions working with pre-cooled solutions and centrifuge 
to avoid unspecific labeling. Briefly, cells were resuspended in MACS buffer (PBS + 0.5% BSA 
+ 2mM EDTA, pH 7.2) and incubated for 5 minutes with a Biotin-Antibody Cocktail containing 
biotin-conjugated monoclonal antibodies against antigens not expressed on NK cells. Next, 
the cells were incubated for 10 minutes with a MicroBead Cocktail containing magnetic 
microbeads coupled to anti-biotin antibodies. The cells were then passed through a LS 
Separation Column attached to a midiMACS magnet and collected, the column was washed 
three times with 3ml of MACS buffer. Finally, the collected NK cells were centrifuged for 10 
minutes at 400 g, resuspended in 3 ml of complete medium and counted. 
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5.5.2   Flow activated cell sorting  
 
Flow activated cell sorting (FACS) uses the technology of flow cytometry (explained in 
section 6.7) to separate cells based on the phenotypic characteristics previously specified by 
the examiner. In brief, a heterogeneous mixture of cells is stained with fluorescent antibodies 
that target the markers of interest. The cells are then analyzed in the flow cytometer to identify 
the populations of interest. The selected populations are separated by using a vibrating 
mechanism to distribute each cell in electrically charged single droplets; the droplets that 
contain the desired cell type are then directed into a collection tube by using electrostatic 
attraction.  
The separation of NK cell subsets using FACS was performed by the team members of 
the flow cytometry lab of the BCRT, using a BD FACSAria II cell sorter. Before sorting, cells 
from the lymph nodes and spleen were isolated with Histopaque gradient centrifugation (see 
section 6.4.2) and stained up to 50 x 106 cells in a total volume of 200 µl as described in section 
6.7.2. The stained cells were handed to the Flow Cytometry lab and the separated cells were 
returned in 1 ml tubes with FACS buffer. 
 
5.6 In vitro assays 
5.6.1   Cell culture  
 
In some experiments, immune cells obtained from mouse tissue were cultivated before 
or after cell sorting for hours to days under physiological conditions. These experiments were 
performed under a laminar flow hood under aseptic conditions. The tools and material used in 
the hood were previously sterilized by autoclaving them at 120°C, 1 bar when possible and 
disinfecting them with 70% ethanol. In addition, sterile buffers, cell culture plates, pipettes and 
tubes were purchased. The cells were cultured in complete medium, in an incubator at 37°C 
with 5% CO2 and 95% humidity.  
 
5.6.2   Cell counting  
 
To determine the number of live cells in a suspension, the cells were mixed with Trypan 
blue, a dye that enters through the damaged membrane when cells die. In this way, the blue 
colored dead cells can be distinguished from the live bright cells. Cells were counted in a 
Neubauer chamber that contains visible quadrants where the cells lie. A cell sample 
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suspended in a defined volume (V) were diluted in a defined ratio with trypan blue (usually 
1:10). Ten µl of the mix was applied to the chamber and the cells were counted under the 
microscope with a manual counter in at least two quadrants. The average of the cells in one 
of the quadrant was obtained (n) and the total number was calculated with the following 
formula:  
Total number of cells = n x trypan blue dilution factor x V x 10 000 (chamber factor) 
 
5.6.3 Stimulation of immune cells  
 
Splenocytes, lymph node cells, immune cells isolated from the CNS or MACS/FACS 
isolated NK cells were stimulated in vitro in round bottom 96 well plates in a concentration of 
100 000 cells per well, or in 48 well plates in a concentration of 106 cells per well. To test the 
production of cytokines, cells were stimulated in complete medium with either 50 ng/ml of PMA 
and 5 µg/ml of Ionomycin, or with 5 ng/ml of IL-12 and 50 ng/ml of IL-18 in the presence of the 
protein transport inhibitor Brefeldin A (10µg/ml) for 5 hours at 37°C. As a control, cells were 
cultured with Brefeldin A without stimulants. In CXCL10 assays, cells were incubated with 
different concentrations of CXCL10 in complete medium in the presence of IL-15 (50 ng/ml) 
when incubated for more than 4 hours. After stimulation, the cells were washed with complete 
medium (centrifuged at 400 g for 7 minutes) for further analysis.  
 
5.7 Flow cytometry  
 
Flow cytometry is the most used technology to analyze physical and chemical 
characteristics of thousands of individual cells in a “real time” manner. This laser-based 
technology incorporates the use of a hydrodynamic flow that focuses a cell suspension into a 
single cell stream that passes through a beam of light. The light scattered by each cell as it 
passes through the beam is measured in two angles to determine the physical characteristics 
of the cell such as size and internal complexity. The forward scatter detector (FSC) is at the 
opposite side of the ray of light and determines the relative size of the cells, while the sideward 
scatter detector (SSC) located perpendicular to the ray of light, provides information about the 
granularity of the cells. Information about the size and granularity is useful to distinguish among 
different populations of cells in a sample, for example, NK cells are part of the lymphocyte 
population, which is small and have low granularity compared with the neutrophils, which are 
larger and have multilobed nucleus and numerous granules in the cytoplasm. The flow 
cytometer is also equipped with laser beams of specific wavelengths that excite fluorescent 
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dyes or flourochromes coupled to antibodies that target surface or intracellular components of 
the cells. The fluorescence emitted passes through special arrays of filters to guide a 
determined wavelength to the sensors that detect fluorescence at specified wavelengths, 
called photomultiplying tubes (PMTs). The PMTs convert the light signal into voltage and 
amplify it to finally be detected and analyzed by a computer workstation (208). New cytometers 
such as the Cytoflex from Beckman Coulter incorporate avalanche photo diodes detectors 
instead of PMTs to detect the fluorescence signals.  
The emission spectra of some fluorochromes partly overlap; as a consequence, one 
fluorochrome can be detected in more than one PMT leading to false positive signals. 
Therefore, and automatic or manual compensation has to be done to subtract the spillover 
signal.  
The flow cytometer used in the current study was a BD Fortessa™ coupled to the 
acquisition software FACSDiva™. Compensation was done using single stained cells or beads 
in the FlowJo software version 10.4. Flow cytometry analysis was also done in the FlowJo 
software. Fluorescence minus one controls were used to define the gate of the positive 
population.  
 
5.7.1   List of antibodies and reagents used for flow cytometry 
 
Each antibody was titrated in using cells with a known expression of the marker to 
determine the optimal working dilution. The antibodies purchased were manufactured to target 
mouse proteins. 
 
Target Fluorochrome Clone Dilution Company 
 
CD3 
 
CD11b 
CD16/CD32  
(Fc Block) 
CD19 
CD27 
 
CD45 
CD49a 
 
PacBlue 
FITC 
APC-Cy7 
- 
 
Biotinylated 
Biotinylated 
PE-Cy7 
FITC 
PE-Vio770 
 
500A2 
145-2C11 
M1/70 
2.4G2 
 
6D5 
LG.7F9 
LG.7F9 
30-F11 
REA493 
 
1:100 
1:100 
1:50 
1:50 
 
1:200 
1:200 
1:50 
1:200 
1:50 
 
BD Biosciences 
BD Biosciences 
BD Biosciences 
BD Biosciences 
 
Biolegend 
eBioscience 
eBioscience 
eBioscience 
Miltenyi Biotec 
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CD49b 
 
CD69 
CD90.2 
(Thy1.2) 
CD103 
CD127 (IL-7Rα) 
CD200R 
CCR2 
CCR7 
cKit 
CXCR3 
CXCR4 
CXCR6 
CX3CR1 
DNAM-1 
Eomes 
FcεRIα 
Gr-1 
IFN-γ 
Ki67 
NK1.1 
NKp46 
Perforin 
RORγt 
 
Streptavidin 
Tbet 
 
TNF-α 
TRAIL 
Biotinylated 
PE-Dazzle596 
PerCP-Vio700 
AF-700 
 
Biotinylated 
PE 
PE 
AF-647 
AF- 488 
Brilliant Violet-605 
Brilliant Violet -510 
PE 
PE 
PerCP-Cy5.5 
PE 
PEeF610 
Biotinylated 
Biotinylated 
PE 
PerCP-eF700 
APC 
PE 
PE 
BV786 
PE 
Brilliant Violet-650 
Brilliant Violet-711 
PE-Vio-615 
PerCP-Cy5.5 
Biotinylated 
DX5 
DX5 
HI.2F3 
30-H12 
 
2E7 
A7R34 
OX-110 
SA203G11 
4B12 
ACK2 
CXCR3-173 
2B11 
DANID2 
SA011F11 
480.1 
Dan11mag 
MAR-1 
RB6-8C5 
XMG1.2 
SolA15 
PK136 
29A1.4.9 
S16009A 
Q31-378 
Q31-378 
- 
4B10 
REA102 
MP6-xt22 
N2B2 
1:200 
1:100 
1:10 
1:200 
 
1:200 
1:50 
1:200 
1:100 
1:100 
1:100 
1:50 
1:100 
1:50 
1:50 
1:200 
1:50 
1:200 
1:200 
1:25 
1:1000 
1:50 
1:50 
1:500 
1:50 
1:800 
1:400 
1:50 
1:30 
1:150 
1:100 
Biolegend 
Biolegend 
Miltenyi Biotec 
Biolegend 
 
Biolegend 
Biolegend 
Biolegend 
Biolegend 
eBioscience 
Biolegend 
Biolegend 
BD Biosciences 
eBioscience 
Biolegend 
Biolegend 
Biolegend 
Biolegend 
Biolegend 
eBioscience 
eBioscience 
Miltenyi Biotec 
Miltenyi Biotec 
Biolegend 
BD Biosciences 
BD Biosciences 
Biolegend 
Biolegend 
Miltenyi Biotec 
eBioscience 
Biolegend 
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5.7.2   Staining of cells for flow cytometry  
 
Up to 3 x 106 cells were stained in 1.10 ml Micronic tubes in in a total volume of 50 µl of 
FACS buffer at 4°C. First, cells were incubated for 15 minutes with 25 µl of anti-mouse 
CD16/CD32 (Fc-Block) to block the Fc-Receptors. Afterwards, a cocktail of monoclonal anti-
mouse antibodies targeting surface markers were added and incubated for 20 minutes. When 
biotinylated antibodies were used, the cells were washed with 1 ml of FACS buffer, centrifuged 
at 400 g for 10 min, resuspended in FACS buffer containing fluorophore-coupled streptavidin 
and incubated for 15 minutes at 4°C. The cells were finally washed with 1 ml of FACS buffer, 
centrifuged, resuspended in 100-200µl of FACS buffer and transferred to (FACS) tubes to be 
analyzed in the flow cytometer. Each sample was filtered through a 30 µm pore filter cap before 
placing it in the flow cytometer. 
For intracellular staining, the cells were washed with PBS after surface staining and 
resuspended in 2% paraformaldehyde (PFA) diluted in PBS to fix them during 20 minutes at 
room temperature in the dark. Next, the cells were washed with 800 µl of saponin buffer (0.5% 
saponin diluted in FACS buffer) to permeabilze the cell membrane. The cells were then stained 
for 20 minutes at 4°C with the antibody mix diluted in saponin buffer. The cells were finally 
washed with 1 ml of saponin buffer and resuspended in PBS to be analysed in the flow 
cytometer.  
For intranuclear staining, the eBioscience™ Foxp3 / Transcription Factor Staining Buffer 
Set was used to fix and permeabilize the cells according to the manufacturer’s instructions. 
This kit was also used to stain intracellular targets together with intranuclear targets.   
 
5.8 Statistics 
 
Two-tailed, parametric T-test was used for two-group comparisons. Gaussian distribution 
of the variables was confirmed with the Kolmogorov-Smirnov normality test. Some groups 
failed to pass the normality test due to the presence of an outlier, in that cases a parametric 
test was used nonetheless. For non-normally distributed variables, a non-parametric Mann-
Whitney test was used instead. A p value <0.05 was considered significant and was depicted 
as *= p<0.05, **=p<0.01 and ***=p<0.001. All statistical analysis was performed in GraphPad 
Prism 5 and 8. 
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6 Results  
 
6.1 Characterization of the chemokine receptors of immature NK cells in the CNS  
 
6.1.1 CX3CR1 mediate the recruitment of mature NK cells to the CNS during 
neuroinflammation 
 
Throughout the first year of my PhD, I focused together with my colleague L. Hertwig in 
defining the chemokine tools that aids on the migration of mature NK cells into the CNS. We 
made use of the transgenic mice deficient on the fraktalkine (CX3CL1) receptor, the CX3CR1, 
on the C57Bl/6 background. In these mice, the CX3CR1 locus was substituted by a reporter 
green fluorescent protein (GFP) and is interchangeably referred as CX3CR1GFP/GFP or 
CX3CR1-/- mice (Huang 2006). To evaluate the NK cell subsets that are recruited into the CNS 
during neuroinflammation, EAE was induced in these mice. We found that CX3CR1-/- mice 
have a reduced migration of mature NK cells into the CNS compared to the WT mice (Figure 
1A). We then performed adoptive transfer experiments in which CX3CR1-/- recipient mice were 
transferred intravenously with isolated NK cells (0.5 – 1 x 106 cell per mouse) derived from WT 
or CX3CR1-/- mice, or PBS as a control.  With these experiments, we showed that the mice 
that received WT (CX3CR1+/+) NK cells had a higher proportion of mature NK cells in the CNS 
at day 20 post immunization than the mice that received CX3CR1-deficient NK cells (Figure 
1B). This was accompanied with a reduction on the EAE severity (Figure 1C), indicating a 
protective role of mature NK cells during neuroinflammation. The figure 1 summarizes these 
findings. The complete data is available in the published manuscript which I co-authored in:  
Hertwig L, Hamann I, Romero-Suarez S, et al. CX3CR1-dependent recruitment of mature NK 
cells into the central nervous system contributes to control autoimmune neuroinflammation. 
Eur J Immunol. 2016;46(8):1984-1996. 
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Figure 1. CX3CR1-dependent recruitment of mature NK cells into de inflamed CNS. A) EAE was 
induced in WT and CX3CR1-/- mice (n = 10 and n = 8 per group, respectively, from three independent 
experiments) and the NK cell maturation subsets were analysed by flow cytometry in the different organs 
at day 20 post immunization (p.i.). The ratio of immature (CD11b-) to mature (CD11b+) NK cells is 
shown. B) NK cells isolated from WT and CX3CR1-/- mice were transferred intravenously into CX3CR1-/- 
mice one day before EAE induction (n = 9 and n =5 per group, respectively, from three independent 
experiments). PBS injection served as a control (n = 9). The ratio of immature to mature NK cells in the 
CNS at day 20 p.i. is shown. C) Clinical EAE course after the adoptive transfer of WT or CX3CR1-/- NK 
cells or PBS into CX3CR1-/- mice (n = 24 per group, performed in 6 independent experiments). Graphs 
show mean ± standard error of the mean (SEM). *p<0.05; nonparametric Mann-Whitney test. Clinical 
scores were analysed using the Kruskal-Wallis test (with Dunn’s posthoc test) *p<0.05, **p<0.01, 
***p<0.001. Figure adapted from Hertwig et al. 2016. 
 
6.1.2 Immature NK cells are present in the healthy and inflamed murine CNS 
 
Thereafter, I set out to investigate whether immature NK cells were present in the murine 
CNS during neuroinflammation. To identify NK cells and their maturation subsets in the CNS 
by flow cytometry, a quality control gating strategy to exclude duplets and dead cells with 
7AAD, which stain cells with a disrupted membrane, was always performed as seen in Figure 
2A. Mononuclear cells were identified in the forward vs sideward scatter and from there, the 
NK cells were gated as CD45highCD11blow/-CD3-NK1.1+ cells. This gating strategy excluded 
potentially contaminating cells such as B cells (identified by CD19), granulocytes (identified by 
Gr-1) and eosinophils, mast cells and basophils (identified by FcεRIα). Furthermore, all NK1.1+ 
cells were NKp46+ (Figure 2D, solid line). The maturation subsets of NK cells were identified 
with the markers CD27 and CD11b. Figure 2B shows the gating strategy in the naïve and EAE 
mice. As expected, the EAE mice had a higher density of infiltrating cells including monocytes, 
CD3+ T cells and CD3- cells, as well as NK cells. Interestingly, the NK cells in both the naïve 
and the EAE mice comprised all the maturation stages with a significant decrease in immature 
NK cells during EAE (Fig. 2C).  
   55 
 
Figure 2. NK cell maturation subsets in the healthy and inflamed CNS. Single cell suspension from 
murine CNS were stained and analyzed by flow cytometry. A) Representative pseudocolor dot plots 
showing the general gating strategy to select single, live and mononuclear cells in CNS samples. B) 
Representative dot plots showing the gating strategy to detect NK cells and its maturation subsets in 
the naïve and the EAE sick mouse. C) Stacked graph of the frequency of each NK cell maturation subset 
from the NK cell gate (CD3-NK1.1+) in the naïve (n=10) and EAE mice (n=20). Data represents 4 
independent experiments and were analyzed with an unpaired t-test **p<0.01 D) Histogram overlay 
showing the fluorescence intensity of the expression of the indicated markers in the NK cell population 
(solid line) comparing with a non-NK cell gate (dotted line, gate shown in B). Representative figure of 6 
naïve mice.  
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6.1.3 Immature NK cells in the CNS express CXCR3  
 
To better characterize the immature NK cells that are present in the CNS, the expression 
of the chemokine receptors that might aid in the migration of this subset into the CNS was 
evaluated in unmanipulated mice. Based on the known expression of the ligands in the CNS 
(130) and on previous reports of chemokine receptors on NK cell subsets in both mice and 
humans (48,209–211), the chemokine receptors CXCR3, CXCR4, CCR2, and CCR7 were 
selected as candidates to be expressed in immature NK cells. First, the expression of the 
chemokine receptors on the NK cells present in the healthy CNS was analyzed by flow 
cytometry. A big proportion of NK cells expressed CXCR3. In contrast, less than 2% of NK 
cells expressed CXCR4, CCR2 and CCR7 (Fig. 3A). CXCR3 was expressed also in the 
peripheral organs (Fig. 3B) and was specifically expressed in immature NK cells in the CNS 
and the periphery (Fig. 3C). The highest proportion of CXCR3+ NK cells was found in the 
lymph nodes, which is in line with the known enrichment of immature NK cells in this organ.  
 
Figure 3. Chemokine receptors on immature NK cells in the CNS and the periphery A) 
Representative contour plots of the expression of the indicated chemokine receptors plotted against 
NK1.1 on the CNS of naïve mice. B) Graph showing the frequency of CXCR3+ NK cells in the indicated 
organs (n: CNS = 18; LN, Sp, Bl = 12). C) Graph showing the proportion of CXCR3+ cells on the 
indicated maturation subsets of NK cells in the CNS (n= 10) and in the periphery n ≥ 5. LN, lymph nodes; 
Sp, spleen; Bl, blood.    
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6.1.4   CXCR3+ NK cells decrease in the CNS during EAE 
 
As some chemokine receptors are upregulated during inflammation after cell activation, 
the proportion of NK cells expressing the above-mentioned chemokine receptors in the CNS 
of EAE mice was evaluated. There was no change in the expression of CXCR4, CCR2 and 
CCR7 in the NK cells present in the inflamed CNS; however, there was a dramatic decrease 
in the proportion of CXCR3+ NK cells in the CNS of EAE mice.  
 
Figure 4. Expression of chemokine receptors on NK cells during EAE. Graph showing the 
proportion of NK cells expressing the indicated chemokine receptors in the CNS of naïve and EAE sick 
mice analyzed by flow cytometry. N: CXCR3 Naïve= 13, EAE= 20 performed in 4 independent 
experiments; CXCR4, CCR2 and CCR7 = 4 mice per group, performed in 2 independent experiments. 
The difference between the naïve and EAE group was analyzed with an unpaired t-test, ****p<0.0001. 
 
6.1.5 The surface expression of CXCR3 on NK cells decreases after activation with 
CXCL10  
 
The ligands of CXCR3 – CXCL9, CXCL10 and CXCL11 – are induced by IFN-γ and 
hence upregulated in the CNS during MS and EAE (212,213). Thus, I reasoned that the 
downregulation of CXCR3 on NK during neuroinflammation might be due to an increased 
CXCR3 activation by its ligands, which provokes an internalization of the receptor, as has been 
previously reported in T cells (214–216). To test whether this was also the case in NK cells, 
an in vitro assay with CXCL10 was performed. Lymphocytes isolated from the lymph nodes 
(axillar and subiliac lymph nodes), which has the highest proportion of immature CXCR3+ NK 
cells, were cultured together with increasing concentrations of CXCL10 in complete medium 
for 4 hours and the expression of CXCR3 on NK cells was analyzed by flow cytometry. Figure 
5A shows the gating strategy to identify NK cells and CXCR3 in fresh cells isolated from lymph 
nodes. After incubation with CXCL10, the expression of CXCR3 decreased in a dose 
dependent manner as shown in Fig.5B.  
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Figure 5. Surface expression of CXCR3 after CXCL10 ligation. Cells where isolated from the lymph 
nodes of naïve mice and cultured in complete medium for 4 hours in the presence of increasing 
concentration of CXCL10. A) Representative contour plots showing the gating strategy to detect 
CXCR3+ cells in isolated lymph node cell preparation. B) Overlaid histograms showing the fluorescence 
intensity of CXCR3 expression on fresh NK cells from fresh LN cells and after 4 hours of incubation with 
the indicated concentrations of CXCL10. The percentage of CXCR3+ cells is plotted at the right. The 
CXCR3+ gate was defined with a fluorescence minus one control (FMO) as seen in the histogram 
overlay. Data from two independent experiments.   
 
6.1.6 Activation of CXCR3+ NK cells with CXCL10 does not induce NK cell maturation 
nor IFN-γ secretion 
 
It has been reported that the activation of CXCR3 with CXCL10 induces the polarization 
of activated T cells into Th1 IFN-γ producing cells (217). Based on that, it was explored whether 
the signaling through CXCR3 in NK cells influence their maturation status and IFN-γ 
production. First, an in vitro assay using a high concentration of CXCL10 (500 ng/ml) in isolated 
NK cells from spleen and lymph nodes was performed. After 4 hours of incubation, the 
maturation status of NK cells remained unchanged (Fig. 6A). The assay was then performed 
with FACS sorted CXCR3+ NK cells from spleen and lymph nodes incubated for 48h with a 
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lower concentration of CXCL10 (100 ng/ml), as in Zohar 2014. The culture was supplemented 
with 50 ng/ml of IL-15 to support the survival of NK cells (Fig. 6B). As a positive control, cells 
were stimulated with IL-12 and IL-18, which induced NK cell maturation and IFN-γ secretion. 
Again, the long-term stimulation of CXCR3+ NK cells with CXL10 did not induce NK cell 
maturation or IFN-γ secretion (Fig. 6C). 
 
Figure 6. Maturation of NK cells after short and long term incubation with CXCL10. A) NK cells 
from the spleen and lymph nodes were isolated by untouched magnetic cell sorting (MACS) and 
incubated for 4 hours in complete medium in the absence or presence of 500 ng/ml CXCL10. The 
maturation stages were then analysed by flow cytometry. Contour plots show the mean percentage of 
each population, at the right, overlaid histogram show the fluorescence intensity of CD11b and CD27 of 
the incubated NK cells. Representative figures from 3 independent experiments. B) Overlaid histogram 
of the fluorescence intensity of 7AAD after 48h incubation of sorted CXCR3+ NK cells in complete 
medium with or without 50 ng/ml of IL-15. C) Sorted CXCR3+ NK cells were incubated for 48 hours in 
complete medium supplemented with IL-15 (50 ng/ml) in the presence of CXCL10 (100 ng/ml) or IL-12 
(5 ng/ml) and IL-18 (10 ng/ml). The maturation status and intracellular IFN-γ was analysed by show 
cytometry. For IFN-γ analysis, Brefeldine A (10 µg/ml) was added to the culture for the last 5 hours of 
incubation. Representative contour plots and overlaid histograms of 3 independent experiments.  
   
6.1.7 Anti-CXCR3 antibody treatment does not alter the proportion of immature NK 
cells in the CNS of EAE mice  
 
After confirming that immature NK cells that express CXCR3 downregulate their receptor 
surface expression after CXCL10 ligation, without altering their maturation and activation 
status, a pilot experiment to explore whether CXCR3 was involved in the recruitment of 
immature NK cells into the CNS during neuroinflammation was performed. For that, mice were 
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treated with five alternating (every third day) intraperitoneal (i.p.) injections of a blocking 
CXCR3 antibody or a IgG isotype as a control (5 mice per group), starting on the day of 
immunization. The mice were sacrificed 3 days after the last injection (day 15), at a time when 
mice normally show clinical disease. Figure 7A shows a scheme of the experimental design.  
The presence of NK cells and its maturation stages were subsequently compared 
between the groups in the brain, spinal cord (SC), lymph nodes (LN), spleen and blood by flow 
cytometry (Fig. 7B, C). Unfortunately, 3 of the mice in the anti-CXCR3 group and 2 of the 
isotype control group did not survive the treatment regimen due to complications from the 
repeated i.p. injections. Of note, only one mouse in the control group showed signals of clinical 
disease at the day of sacrifice. There was no change in the proportion or numbers of NK cells 
in the different organs between the anti-CXCR3 and control group (Fig. 7B). In addition, the 
maturation subsets were unchanged between the groups in all the organs except in the spleen, 
where a lower proportion of immature (DN: CD27-CD11b- and CD27+CD11b-) and a higher 
proportion of mature (CD27-CD11b+) NK cells was found in the mice treated with anti-CXCR3 
antibody (Fig 7C). Despite the low power of the experiment, the results suggest that CXCR3 
is important for the homing of immature NK cells into the spleen during inflammation. A higher-
powered experiment would be necessary to exclude the involvement of CXCR3 in the 
recruitment of NK cells into the CNS.  
 
Figure 7. Effect of anti-CXCR3 treatment during EAE on the recruitment of NK cells into the CNS 
and periphery. A) EAE was induced and the mice received five i.p injections of anti-CXCR3 or control 
isotype IgG (200 µg diluted in PBS, each) every third day as shown in the scheme. B) Graphs showing 
the percentage and numbers of NK cells in each organ determined by flow cytometry. C) Graphs 
showing the percentage of each maturation subset from the NK cell gate in each organ analyzed by flow 
cytometry. N: anti-CXCR3 = 2, isotype control = 3. Graphs show mean + SEM. The groups were 
analyzed with an unpaired t-test *p<0.05, **p<0.01. SC, spinal cord; LN, lymph nodes; DN, double 
negative CD27-CD11b-; DP, double positive CD27+CD11b+. 
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6.2 Identification of different ILC group 1 subsets in the CNS 
 
The presence of NK cells in the CNS during steady state suggest the possibility that 
some of them might represent tissue resident cells, i.e. ILCs. Furthermore, the expression of 
CD27 and CXCR3 has been reported in liver ILC1s (17,56,61), which supports the idea of a 
ILC1 population on the CNS that express ‘immature NK cell’ markers. Therefore, I decided to 
characterize the CNS CD3-NK1.1+ cells in the new ILC frame and include markers that would 
provide more detail about their true identity.  
 
6.2.1   Immature NK cells express the ILC1 marker CD49a 
 
The markers CD49a and CD49b were used to distinguish between ILC1 and 
conventional NK cells, respectively. We gated on the conventionally identified NK cell 
maturation subsets as shown in Figure 1 and analysed the expression of CD49a and CD49b 
within the maturation subsets excluding the DN subset due to the low number of cells. More 
than half of the immature CD27+CD11b- NK cells expressed CD49a and lacked the expression 
of CD49b. On the other hand, the mature (CD27+CD11b+) and terminally mature (CD27-
CD11b+) NK cells were mostly CD49a-CD49b+ (Figure 8). This data suggest that a 
considerable fraction of the cells previously recognized as immature NK cells present in the 
healthy CNS are not conventional NK cells but ILC1s.   
 
Figure 8. Expression of CD49a and CD49b in the NK cell maturation subsets. Representative 
contour plots showing the expression of CD49a and CD49b in the different NK cell subsets of the CNS 
of naïve mice. The numbers indicate the mean percentage of each subset of n = 6. At the right, a 
visualization in pie charts show the proportion of the CD49a+CD49b-, CD49a+CD49b+ and CD49a-
CD49b+ populations within the NK cell maturation subsets.  
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6.2.2   CD3-NK1.1+ CNS cells comprise diverse ILC populations 
 
Next, the proportion of the subsets identified by the integrins CD49a and CD49b were 
assessed directly in the (CD45highCD11blow/-)CD3-NK1.1+ cells of the CNS comparing with the 
liver, which is known to contain both conventional NK cells and ILC1s, and the spleen, which 
is known to contain NK cells but very little ILC1s. Similar to the liver, about 30% of CNS CD3-
NK1.1+ cells were CD49a+CD49b- while about 60% were CD49a-CD49b+; in addition, about 
10% of the CD3-NK1.1+ cells expressed both CD49a and CD49b (Fig. 9A). As expected, most 
CD3-NK1.1+ cells of the spleen were CD49b+ (Fig 9A).  
To confirm the identity of the identified subsets we performed flow cytometry analysis of 
the transcription factors Eomes, Tbet and RORγt. The CD49a-CD49b+ subset expressed Tbet 
and Eomes, confirming their NK cell identity; while CD49a+CD49b- cells were Tbet+Eomes-, 
confirming their ILC1 identity. Interestingly, within the CD49a+CD49b+ subset, about half were 
Eomes+ and half Eomes-, which could represent an intermediate stage between NK and ILC1 
cells as has been previously reported (68). Therefore, this population was designated 
intermediate (int) ILC1s. Furthermore, none of the subsets contained ILC3s as they did not 
express RORγt (Fig. 9B). However, it is known that ILC3s can differentiate into ILC1 by 
decreasing RORγt after IL-12 stimulation. Therefore, to determine whether some of the ILC1s 
had an ILC3 origin (i.e. ex-ILC3s) the genetic fate mapping (fm) mouse for RORγt (Rorc-
CreTg;Rosa26RRFP/+, referred as RORcfm) was used. In this mouse, all the cells that ever 
expressed RORγt (Rorc gene) are permanently and heritably marked with the red fluorescent 
protein (RFP), even if they subsequently lose RORγt expression (93). Interestingly, about 35% 
of both the ILC1s and intILC1s were ex-ILC3s (34.6 ± 4.4 and 35.7 ± 7.2 %, respectively), while 
less than 3% of the NK cells were RFP+ (2.9 ± 1.4 %) (Fig. 9C).  
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Figure 9. Identity of the NK1.1+ CNS populations defined by the expression of transcription 
factors. CD45highCD11b-/lowCD3-NK1.1+ cells gated as shown in figure 1 were analysed for the 
expression of CD49a and CD49b and the transcription factors that define their identity. A) 
Representative contour plots of the expression of CD49a and CD49b in the CD3-NK1.1+ population of 
the CNS, spleen and liver. At the right, the graph shows the mean proportion of each subset in each 
organ, n ≥ 5. B) Representative contour plots showing the expression of Eomes, Tbet and RORγt in the 
different CD3-NK1.1+ subsets of the CNS, at the right the graph shows the proportion of Tbet+Eomes+ 
cells in each subset, n = 5. C) Representative contour plots of the expression of RFP in the RORc-fm 
mouse in each of the CNS CD3-NK1.1+ subsets, the graph at the right shows the proportion of RFP+ 
cells in each subset, n = 3.  
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6.2.3   NK cells present in the CNS have a mature phenotype, ILC1s are CD11blow and 
CD27+ 
 
To clarify the phenotype of the bona fide NK cells present in the CNS, the maturation 
markers were reassessed in the CD3-NK1.1+CD49a-CD49b cells (from now on referred as 
NK cells) and the CD3-NK1.1+CD49a+CD49b- cells (from now on referred as ILC1s). As 
shown in Fig. 10 A, the NK cells present in the CNS have a predominantly mature phenotype, 
with less than 15% of them constituting immature NK cells. In the case of ILC1s, cell subsets 
could not be classified as in the NK cells, but it was found that ILC1s have a low expression of 
CD11b and that most of them are CD27+. Furthermore, the expression of CXCR3 was 
reanalysed in the bona fide NK cells of the CNS. Still, a fraction of immature and mature NK 
cells expressed CXCR3, but it was not expressed in fully mature NK cells (Fig. 10B). 
 
Figure 10. Maturation markers and CXCR3 in the group 1 ILCs of the CNS. A) Comparison of the 
expression of the markers CD27 and CD11b in the NK cells and ILC1s of the CNS, the numbers in the 
contour plot represent the proportion of each population in a concatenated sample of 3 mice. On the 
right side of panel A, a representative histogram overlay shows the fluorescence intensity of CD11b and 
CD27 in the NK cells and ILC1s. B) Contour plot overlaid of the NK cell maturation subsets showed in 
A, displaying the expression of CXCR3. The purple population represents the CD27+CD11b- subset, 
the gray the CD27+CD11b+ subset and the green the CD27-CD11b+ subset. Numbers represent the 
proportion of CXCR3+ cells. 
 
6.2.4  ILC1s of the CNS are characterized by the expression of CXCR6, TRAIL and 
DNAM-1 
 
After confirming that the NK1.1+ cells in the CNS are composed of different ILC 
populations, the ILC1 subset was further characterized in comparison with the NK cells. 
Therefore, the expression of diverse markers that are characteristic of ILC1s or NK cells were 
assessed. The intILCs were excluded from the analysis because of their reduced number and 
mixed identity. In addition, the ‘ex-ILC3’ that are part of the ILC1 population were included, as 
it has been shown that ILC3s and ex-ILC3s adapt their phenotype to the tissue 
microenvironment where they reside (87).  
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As expected, ILC1s expressed the tissue resident marker CD69 (79 ± 2 %), however 
they did not express the integrin CD103. Most notably, all ILC1s homogeneously expressed 
CXCR6 (97 ± 0.8 %), TRAIL (81 ± 6%) and DNAM-1 (96 ± 1 %). Furthermore, DNAM-1 
expression was high in all the ILC1s and intermediate in the NK cells (DNAM-1 gMFI ILC1s = 
24927; NK cells = 1760; p<0.0001). The distinctive marker of ILCs, the IL-7Rα was expressed 
in ILC1s in a heterogeneous manner (24 ± 2 %) while Thy1.2 expression was more frequently 
expressed in ILC1s (81 ± 4 %) as well as the recently proposed ILC1 marker CD200R (58 ± 
5%). Interestingly, Perforin was also expressed in ILC1s (95 ± 1 %) but in a significant lower 
density than in the NK cells (perforin gMFI ILC1s = 2316; NK cells = 10561; p=0.006). Finally, 
c-Kit, a marker expressed in LTis and some ILC3 and ILC2 subsets, was not expressed in the 
CNS group 1 ILCs. 
 
Figure 11. Phenotypic profile of group 1 ILCs of the CNS. Histogram overlays showing the 
expression of the indicated marker in the ILC1 and NK cell subset from the CNS. FMOs (from the CD3-
NK1.1+ gate) are included as a reference for negative expression of the marker. Representative 
histograms of n ≥ 4 mice, from at least 2 independent experiments.  
 
6.2.5   Besides CXCR3, ILC1s modulate TRAIL expression 
 
After defining the phenotype of the CNS ILC1s, their response during neuroinflammation 
was next examined. Since it is known that inflammatory signals can modify the surface integrin 
expression in immune cells, it was first defined whether the surface expression of CD49a and 
CD49b were still a valid marker for the identification of group 1 ILC subsets during 
neuroinflammation. At peak EAE, the ILC1s, intILC1s and NK cells identified by the surface 
expression of CD49a and CD49b, expressed the expected transcription markers in the same 
way as in the naïve mouse. Interestingly, the inflammatory microenvironment had no effect in 
the proportion of intILC1s that expressed Eomes (Fig 12, left upper panel). These data indicate 
   66 
that CD49a and CD49b are reliable markers to identify the different ILC group 1 subsets in a 
context of Th1/Th17 inflammatory environment, as is the case in the EAE. 
Next, the stability of some of the defining ILC1 markers like DNAM-1, TRAIL, CD69 and 
IL-7Rα during neuroinflammation was explored. Most of the markers displayed the same 
expression pattern in the EAE sick mice as in the naive mice, except for CXCR3 (Fig. 12 right 
lower panel), which expression decreased in the ILC1s and NK cells as previously shown (Fig. 
4). In addition, the percentage of ILC1s expressing TRAIL decreased during EAE (Fig. 12 
middle lower panel). In addition, an increase of CD69 expression was also detected in the NK 
cells in the EAE mice (Fig 12 right upper panel).  
 
Figure 12. Transcription factor and surface marker expression during EAE. The expression of the 
indicated markers was compared between naïve (open bars) and EAE sick (black bars) mice in the ILCs 
and NK cells from CNS samples. N: transcription factors = 5 per group; surface markers ≥ 4 per group. 
Data from at least 2 independent experiments. The difference between the naïve and EAE group was 
analysed with a t-test *p<0.05, **p<0.01, ***p<0.001. gMFI, geometric mean fluorescence intensity.  
 
6.2.6   ILC1s express more TNF-α than NK cells in the healthy and inflamed CNS 
 
Next, the capacity of each subset to secrete the signature type I cytokines IFN-γ and 
TNF-α was explored. Cells isolated from naïve CNS were incubated with IL-15 and IL-12, which 
is known to induce IFN-γ secretion in both NK cells and ILC1s. Indeed, a high proportion of 
IFN-γ expressing cells was detected by flow cytometry after IL-15 and IL-12 stimulation, 
however, there was no production of TNF-α (Fig 13A). A more general stimulation protocol 
was performed using PMA and Ionomycin. This elicited also the production of IFN-γ. However, 
only ILC1s produced TNF-α. This was confirmed in cells derived from the CNS of sick EAE 
mice, that were restimulated with PMA and Ionomycin (Fig 13B). IFN-γ was produced by ILC1s 
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and NK cells in a comparable manner (as measured by the geometric mean fluorescence 
intensity (gMFI) of IFN-γ). However, a higher frequency of ILC1s expressed TNF-α and the 
expression was also more intense (Fig. 13B). Interestingly, the proportion of ILC1s producing 
both IFN-α and TNF-α was also higher in comparison with NK cells (Fig. 13B). Interestingly, 
the comparison of the cytokine production between the cells isolated from the naïve and EAE 
CNS revealed that NK cells, but not ILC1s, produce significantly more cytokines during EAE 
(Fig. 13C).  
 
 
Figure 13. Cytokine production of group 1 ILCs of the CNS. Cells obtained from the CNS were 
stimulated for 5 hours in the presence of stimulants and Brefeldine A, stained for intracellular IFN-γ and 
TNF-α and analysed by flow cytometry. A) Representative contour plots showing the expression of IFN-
γ and TNF-α in CNS from naïve mice after stimulation with IL-15 (50 ng/ml) and IL-12 (10 ng/ml) or PMA 
(50 ng/ml) and Ionomycin (Iono) (1µg/ml). The numbers are the mean percentage of 3 mice for each 
condition. B) Graph shows the mean + SEM of cytokine expression quantified as the percentage of 
expressing cells and gMFI in the ILC1 and NK cells of the CNS from sick EAE mice, stimulated with 
PMA and Ionomycin as in (A) N= 3, C) Percentage of cytokine expressing NK cells (left) and ILC1s 
(right) comparing between cells obtained from the CNS of naïve and EAE mice, N=3. Difference between 
groups was analysed with a t-test.  * p<0.05, **p<0.01, ***p<0.001. 
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6.2.7   Group 1 ILCs are differentially distributed within the CNS compartments and are 
increased in the brain parenchyma during EAE 
So far, the characterization of group 1 ILCs was performed in the whole CNS that include 
the brain with its choroid plexuses, the spinal cord and possibly traces of leptomeninges, 
specially pia matter. Since ILCs are known to be enriched in barrier structures, it was 
interesting to define whether the group 1 ILCs had a preferential location within the CNS 
compartments. Therefore, the choroid plexus was removed from the brain ventricles, and the 
dural meninges from the skull cap of the same mouse and the proportion and number of each 
subset was analyzed in the naïve and EAE condition. Interestingly, while in the naïve mouse, 
a dominance on the proportion of ILC1s was observed in all the compartments, during EAE, 
an overall increase of NK cells was observed, with a significant increase observed only in the 
brain parenchyma (Fig. 14 right panel). The choroid plexus was enriched with ILC1s and 
contained very low numbers of NK cells in the naïve mice (Fig. 14 middle panel). From the 
three compartments, the meninges contained the higher numbers of cells, that comprised all 
group 1 ILC subsets (Fig. 14 lower panel), as well as in the brain, where a significant increase 
of ILC1s and most notably of intILC1s and NK cells was observed during EAE (Fig 14 upper 
panel).   
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Figure 14. Distribution of group 1 ILCs within the CNS compartments. Representative contour plots 
showing the distribution of group 1 ILCs in the brain devoid of choroid plexus, the choroid plexus and 
the dural meninges. The numbers represent the mean percentage of each population. At the right, the 
graph shows the numbers of each subset normalized to live single cells. The graphs and numbers 
represent 6 mice per group in the brain compartment; 2 mice were pooled together in the case of choroid 
plexus and meninges in each condition, resulting in a n = 3. The naïve and EAE group were analysed 
with a t-test *p<0.05, **p<0.01. Graphs shown mean + SEM.  
 
6.2.8   NK cells, but not ILC1s, proliferate in the CNS during EAE  
 
The increase on NK cells in the brain during EAE is in line with our previous results of 
NK cell recruitment into the CNS during neuroinflammation (115). The increased numbers of 
group 1 ILCs on the brain parenchyma during EAE could also point to a proliferation of these 
subsets in response to neuroinflammation. Therefore, the marker Ki67 – a nuclear protein that 
is necessary for cell proliferation expressed during the active phases of the cell cycle (G1, S, 
G2, and M phases) – was used to assess the presence of proliferating cells by flow cytometry 
in the group 1 ILC subsets of the naïve and EAE mice. Due to the difficulty of performing 
intracellular staining with very low number of cells, like in the choroid plexus, the complete 
CNS was used. Similar to the results of the previous section, and increase in the proportion of 
NK cells and a decrease of ILC1s was found during EAE in comparison to the naïve mouse. 
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Furthermore, the numbers of NK cells but not of ILC1s were increased in the CNS during EAE. 
In concordance, the NK cells expressing Ki67 were higher in the EAE condition, both when 
identified by the surface markers or by the transcription factors (Fig 15B). The intILC1 showed 
a more variable increase in their numbers and expression of Ki67 during EAE that was not 
significant. As the Tbet+Eomes+ cells were the most proliferative during EAE, it was also 
analyzed whether within the intILCs, the Eomes+ subset proliferated more than the Eomes- 
subset. However, neither the proportion of Eomes+ intILC1s nor the proportion of Ki67+ cells 
in the Eomes+ intILC1s was increased during EAE (Fig. 15C). These data indicate that NK 
cells, but not ILC1s, proliferate readily in the inflamed CNS. 
 
 
Figure 15. Proliferation of group 1 ILCs in the CNS during EAE. The numbers and proliferation of 
ILC1s, intILC1s and NK cells in the whole CNS were compared between the naïve and EAE mouse. A) 
Representative contour plot showing the proportion of each group 1 ILC subset in the CNS of naïve and 
EAE sick mouse. Numbers represent the mean proportion of each subset. The graphs at the right shows 
the comparison of the numbers of group 1 ILC subsets defined by the surface markers (left) or the 
transcription factors (right) in the naïve and EAE mouse as mean + SEM. N= 8 per group. B) Intranuclear 
expression of Ki67 was analysed by flow cytometry. The graphs show mean + SEM proportion of Ki67+ 
cells within each subset defined by the surface markers (left) or the transcription factors (right). N = 6 
per group. C) The intILC1 subset was compared between the naïve and EAE condition in the proportion 
of Eomes+ cells represented as a ratio in the graph at the left. The frequency of Ki67+ cells was analysed 
in the Eomes- and Eomes+ intILC1s at the right. The line shows the mean ± SEM. A t-test was used to 
analyse the difference between the groups. *p<0.05, **p<0.01, ***p<0.001. 
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7 Discussion 
 
NK cells, contrary to ILC1s, are able to circulate in the bloodstream, they home and 
reside in tissues like spleen and lung and participate in the immunosurveillance of the CNS 
(150). In the frame of the present thesis, two hypotheses were tested. First, assuming that the 
phenotypically immature NK cells present in the CNS originate from the periphery, the 
chemokine receptors that might contribute to the migration of immature NK cells into the CNS 
were investigated. Second, assuming that the cells identified as NK cells in the CNS are 
include an ILC1 fraction, an in-depth characterization of these cells with ILC defining markers 
was undertaken. The results obtained reveal a previously unrecognized diversity of group 1 
ILCs present in the CNS of healthy mice and point to their differential response during 
neuroinflammation.  
 
7.1 Characterization of the chemokine tools of immature NK cells in the CNS and 
periphery 
 
The CNS is continuously surveilled by leukocytes coming from the periphery. Despite 
the restrictive nature of the CNS barriers, immune cells are found inside the CNS 
compartments, including the brain parenchyma, during steady state. This was recently 
demonstrated in a high dimensional analysis of the brain’s immunological milieu using mass 
cytometry, in which the presence of DCs, neutrophils, monocytes, T cells, B cells and NK cells 
was determined (151). The immune cells present in the healthy CNS differ from circulating 
immune cells, which reflects a selective process at brain barriers like the CP that results in an 
enrichment of anti-inflammatory and immunomodulatory cells (218). This selection involves 
the interplay of chemokines, adhesion molecules, cytokines and their respective receptors 
expressed on the CNS barriers and immune cells. During neuroinflammation, an active 
recruitment and infiltration of immune cells into the CNS parenchyma occurs in a regulated 
manner, thanks to a switch to a pro-inflammatory microenvironment that loosens the restrictive 
nature of the barriers and facilitates cell infiltration (137), However, in advanced stages, a 
disrupted BBB can lead to a massive unregulated immune infiltration.  
We previously showed that during EAE, mature NK cells are selectively recruited to the 
CNS in a CX3CR1-dependent manner. mature NK cells contributed to limit inflammation 
probably by lysing encephalytogenic T cells (115) (Figure 1). Furthermore, NK cells were 
present in CNS not only in EAE mice but also in healthy mice. Therefore, it was interesting to 
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determine the phenotype of NK cells that were present in the CNS during steady state and to 
determine the chemokine receptors that could mediate this recruitment.  
It was found that the NK cells – defined as CD45highCD11b-/lowCD3-NK1.1+ – that are 
present in the CNS of both healthy and EAE sick mice, include immature and mature NK cells 
with a predominance of immature CD27+CD11b- cells in the healthy mice (Figure 2). This 
finding was interesting since immature NK cells are enriched in the lymph nodes, while the NK 
cells present in the blood have a predominant mature phenotype. This suggests a similitude in 
NK cell recruitment mechanisms of the lymph nodes and the CNS. Furthermore, the presence 
of immature NK cells in CNS is in line with our previous report of an enrichment of CD56bright 
NK cells in the CSF of patients with inflammatory diseases (146). 
Therefore, the expression of candidate chemokine receptors was evaluated to 
understand the mechanism of immature NK cell recruitment to the CNS during steady state. 
These candidates were CXCR3, CXCR4, CCR2 and CCR7, selected on the base of the known 
expression of the corresponding ligandsin the CNS, and cosindering the reports on CNS 
infiltration of immune cells that express these particular receptors as well as the known 
chemokine receptor expression of human and mice peripheral NK cells. Human CD56bright NK 
cells, for instance, express CCR7 (210). The endothelial cells of the BBB and the CP 
constitutively express CCL19, one of the CCR7 ligands, and the CSF is enriched with central 
memory T cells that express CCR7 and CXCR3 (145,218,219). Likewise, CXCL12, the ligand 
of CXCR4, is expressed in the abluminal surface of the BBB (138) and is involved in the 
retention of NK cells in the bone marrow (220). CCR2 is important for the recruitment of 
monocytes to the CNS during EAE (221). Finally, the expression of CXCR3 was reported in 
immature NK cells in various organs (48). In the present work, it was found that immature NK 
cells in the CNS express CXCR3 (about 30% of NK cells), and a small proportion CCR2 (less 
than 10%) (Figure 3,4). Because the expression of chemokine receptors is modulated in 
response to cytokines, the expression of these candidates was also evaluated during EAE. In 
this context, the expression of CCR2, CCR7 and CXCR4 on NK cells remained unchanged. 
However, CXCR3 expression dramatically decreased during neuroinflammation (Figure 4). 
This observation led to the investigation of the dynamics of CXCR3 expression on NK cells in 
in vitro experiments using NK cells isolated from lymph nodes and spleen.  
Chemokine receptors are seven-transmembrane-spanning G-protein-coupled receptors 
whose activation is tightly regulated by different mechanisms including desensitization – a fast 
response that uncouples the receptor from the G protein – and internalization, in which the 
receptor is degraded or recycled, resulting in a more prolonged unresponsiveness to the ligand 
(222,223). The internalization of CXCR3 has been demonstrated in activated T cells and 
transfected cells lines (214,215,224). However, whether this is the case also in NK cells has 
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not been investigated. Here, using CXCL10, it was demonstrated that increasing 
concentrations of the CXCR3 ligand results in a disappearance of the receptor from the cell 
surface of NK cells isolated from LN (Figure 5). This result points to an internalization of 
CXCR3, since its downregulation was persistent after 4 hours of incubation with the ligand, a 
long time-frame for signalling dynamics. In addition, it is unlikely that the binding of CXCL10 
could have hindered the anti-CXCR3 antibody binding to detect the receptor by flow cytometry 
because the cells were washed twice with cold PBS before performing the staining, which was 
also performed at 4°C, a non-optimal temperature for receptor-ligand binding kinetics. 
Although CXCR3 has three ligands, only the role of CXCL10 was tested because CXCL10 
binds to the same epitope in CXCR3 as CXCL9, but to a different than CXCL11 (214). The 
role of CXCL11 was not explored because C57BL/6 mice are functionally deficient for CXCL11 
due to a frame shift in the mRNA coding region that causes the truncation of the peptide (213).  
Chemokine receptors, like other G-protein-coupled receptors, display biased signaling 
or functional selectivity. This means that certain situations can elicit the activation of one of 
several available signaling pathways. In the case of CXCR3, it has been shown that in murine 
activated T cells, the receptor activation with CXCL11 promotes a T cell polarization towards 
a Th2 or Tr1 subset, while the activation with CXCL9 or CXCL10 promotes a polarization 
towards a Th1 or Th17 subset. This biased signaling was dependent on STAT1, STAT4 and 
STAT5 in the case of CXCL9/10 activation of the receptor and on mTOR, STAT3 and STAT6 
in the case of CXCL11 activation (217). The effect of CXCR3 signaling in the biology of NK 
cells has not been explored. Therefore, the effect of CXCL10 activation on the maturation and 
IFN-γ production on NK cells was evaluated in the present work. CXCR3 activation with 
CXCL10 did not affect the maturation status nor elicited IFN-γ production on isolated NK cells 
and sorted CXCR3+ NK cells derived from the spleen and LN after short term (4 hours) or long 
term (48 hours) incubation with the ligand (Figure 6). In these assays, NK cells were incubated 
with IL-15 to promote their survival, and their responsiveness was confirmed with the 
stimulation with IL-12 and IL-18 that are known to induce IFN-γ production and NK cell 
maturation (225). IL-12R signaling induces STAT4 phosphorylation that is critical for IFN-γ 
production (226). Therefore, these results suggest that CXCL10-induced CXCR3 signalling 
does not activate STAT4 on NK cells. Yet, effects of CXCL10 on other aspects of NK cell 
biology like cytotoxicity and proliferation were not explored in this study and cannot be ruled 
out. The observed reduction on the percentage of CXCR3+ NK cells found in the inflamed CNS 
may reflect an ongoing activation of the receptor by its ligands, which are upregulated in the 
CP, CSF, astrocytes and perivascular space during neuroinflammation (139,144,212,227); 
Further, the data indicates that this activation does not affect NK cell maturation and IFN-γ 
production.    
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Next, to explore if CXCR3 is involved in the recruitment of immature NK cells to the CNS 
during EAE, EAE mice were treated with a blocking CXCR3 antibody during the course of the 
disease. The results rather suggest, that CXCR3 might be involved in the homing of immature 
NK cells to the spleen, since a significant decreased proportion of immature NK cells and 
higher proportion of mature NK cells was found in that organ at day 15 post immunization in 
the treated mice compared to the IgG control mice (Figure 7). We previously reported a 
mobilization of NK cells in the periphery during the course of EAE. Interestingly, the decrease 
on the number of NK cells in the spleen correlates with an increase on the numbers of NK cells 
in the CNS at day 10 post immunization (115), which points to a mobilization of these cells 
from the spleen to the CNS. Furthermore, the immunization to induce EAE involves a systemic 
immune response to CFA and pertussis toxin i.p. injection protocol. In this context, IFN-γ 
production in response to the immunization protocol might increase the expression of the 
CXCR3 ligands in the spleen. Of note, although Th1 cells preferentially express CXCR3, the 
numbers and percentage of CD3+ T cells in the examined organs was not affected in the mice 
treated with the CXCR3 blocking antibody (not shown). 
In a model of intracerebral infection of a murine coronavirus that expressed CXCL10, it 
was shown that NK cells were recruited to the CNS contributing to the clearance of infection. 
This NK cell recruitment of was detected as early as 2 days post infection (228). In our model, 
the brain was examined at day 15 post immunization, a time when the EAE disease should be 
already stablished (peak disease). The CXCR3 dependent recruitment of NK cells into the 
CNS in earlier stages of the EAE course, like the pre-onset and onset of disease deserves 
further investigation. In addition, the results of the here presented pilot experiment should be 
taken with caution due to its low power (n = 3 and n = 2 in the control-IgG and anti-CXCR3 
group, respectively).  
In sum, these results indicate that immature NK cells express CXCR3, which is actively 
internalized after the engagement with its ligand. However, CXCR3 did not seem to mediate 
the recruitment of immature NK cells into the CNS during inflammation, but rather contribute 
to their homing to the spleen in the EAE model. It is possible that other chemokine receptors 
unexplored in the present study might be involved in the specific migration of immature NK 
cells into the inflamed CNS in the context of EAE.  
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7.2 Identification of different ILC group 1 subsets in the CNS 
  
If the immature NK cells present in the CNS during steady state and inflammation are 
not coming from the periphery, an alternative is that they represent tissue resident cells. ILCs 
are tissue resident cells that have been described in various organs. Due to the phenotypical 
similitudes between NK cells and ILC1s, it was crucial to investigate the CD3-NK1.1+ cells of 
the CNS with more detail to elucidate their true identity and generate appropriate models and 
research questions. The second part of the present study was dedicated to this task, which 
generated new insights into the ILC composition of the healthy CNS and the specific phenotype 
and functionality of the identified ILC1s in comparison to the conventional NK cells.  
The expression of CD27 and CXCR3 on the immature NK cells suggested a possible 
ILC1 identity (17,96). Therefore, the expression of the integrins CD49a and CD49b was also 
investigated to roughly differentiate between ILC1s and NK cells, respectively, within the 
maturation subsets of the CD3-NK1.1+ cells of the CNS. This analysis revealed that immature 
CD3-NK1.1+CD27+CD11b- cells co-expressed CD49a (about 80% of cells) in a higher 
proportion than CD49b (about 20% of cells). Conversely, the mature (CD3-
NK1.1+CD27+CD11b+) and fully mature (CD3-NK1.1+CD27-CD11b+) NK cells co-expressed 
CD49b in high proportion (about 80% of cells), while few or no cells co-expressed CD49a in 
the mature (about 20%) and the fully mature population (less than 5%) (Figure 8). These data 
indicated that a fraction of immature NK cells display a ILC1 phenotype.  
To further confirm the presence of ILC1s, the expression of the same integrin markers 
was evaluated directly in the CD3-NK1.1+ cells. Three populations were identified, a CD49a+, 
a CD49b+ and a double positive population. The transcription factor analysis revealed that 
these populations are Tbet+, but that differentially express Eomes. Eomes expression is 
necessary for the development, maintenance and function of NK cells (25–27). In this line, the 
CD3-NK1.1+CD49b+ expressed Eomes, confirming their identity as conventional NK cells, 
while CD3-NK1.1+CD49a+ were Eomes- indicating a ILC1 identity. Intriguingly, 50% of the 
CD49a+CD49b+ population expressed Eomes+, and was thus termed intILC1s (Figure 9B). It 
is possible that the presently described Eomes+ intILC1s are NK cells with an upregulated 
expression of CD49a and that the Eomes- intILC1s are ILC1s with an upregulated expression 
of CD49b. However, this population has been described in other contexts. On one hand, Gao 
and colleagues found a high proportion of tumor associated CD49a+CD49b+ intILC1s. They 
showed by global transcriptome analysis that intILC1s have a different gene expression profile 
than ILC1s and NK cells, including a low Eomes expression, proposing the intILC1s as an 
independent subset (68). On the other hand, Filipovic and colleagues showed in the uterine 
group 1 ILCs, that a proportion of NK1.1+CD49a+ cells were Eomes+, which they called tissue 
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resident NK (trNK) cells. In this case, transcriptome analysis showed a closer relationship in 
the gene expression profile between trNK cell and ILC1s, than cNK cells and ILC1s. 
Interestingly, uterine ILC1s clustered away from liver ILC1s revealing the uniqueness of the 
uterine ILC1s (101). Furthermore, salivary gland ILC1s are CD49a+CD49b+ and express both 
Tbet and Eomes. However, it was shown that these cells are not dependent on either 
transcription factor. In addition, transcriptome analysis revealed a unique gene expression 
profile of the intILC1s that shared some characteristics with ILC1s and NK cells (92). Similarly, 
a transcriptome analysis would be instrumental in our studies to define the relationship of the 
presently described intILC1s in relationship with the ILC1s and NK cells, as well as to ascertain 
the similitude of the CNS-ILC1s with the ILC1s of other organs like the liver.    
A subset of group 3 ILCs express NK1.1 and NKp46. It was confirmed that ILC3s were 
absent from the here defined CNS group 1 ILCs as none of them expressed RORγt, the 
defining transcription factor of ILC3s. However, ILC3s are able to convert into ILC1s (65,229). 
Therefore, it was also investigated if some of the presently described ILC1s had an ILC3 origin 
by using the RORc-fate mapping mouse that permanently marks cells that expressed RORγt 
at some point during their ontogeny. In this way, it was revealed that about 35% of the ILC1s 
and intILC1s have an ILC3 origin (Figure 9C). Ex-ILC3s were also found in a similar proportion 
in the liver (33 ± 5 %) of the same mice (data not shown). Thus, it would be interesting to 
determine in future experiments the baseline proportion of ex-ILC3s in the different tissues and 
how that changes in response to inflammatory challenges. Importantly, a differential 
functionality of ex-ILC3s has been reported. In the gut, ex-ILC3s were found to exacerbate 
experimental colitis (93). RORcfm+ ILCs (which include exILC3s and ILC3s) were found to have 
more potent anti-tumoral properties than RORcfm- ILCs in the spleen (87). Therefore, it is of 
great interest to address in future experiments the differences between the CNS ILC1s and 
ex-ILC3s on a functional level.  
On the other hand, it was shown in adoptive transfer experiments that the phenotype of 
RORcfm+ ILCs is shaped by the tissue microenvironment. For example, transferred RORcfm+ 
ILCs isolated from the spleen homed to different organs, when recovered from the host organ 
they no longer displayed a spleen-ILC phenotype but an ILC phenotype characteristic of the 
organ, like a low Thy1.2 expression if recovered from the liver, or a high Thy1.2 expression if 
recovered from the small intestine lamina propia (87). These data indicate that the phenotype 
of RORcfm+ ILCs, and probably of ILCs in general, is imprinted by the tissue microenvironment 
where they reside. Thus, the elucidation of the specific phenotype of the ILCs that reside in 
such a unique organ as the CNS is of great interest.  
Once the group 1 ILC subsets of the CNS were defined, the re-assessment of the 
maturation stages of bona fide NK cells present in the CNS was imperative. It was found that 
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CD3-NK1.1+CD49b+ comprise mostly mature and fully mature NK cells with a small fraction 
of immature cells (10% of NK cells) (Figure 10A), these immature NK cells expressed CXCR3 
in a lower proportion than previously defined (15% vs 60% of immature NK cells, figs. 10B and 
3C, respectively). The ILC1s could not be classified by the classical NK cell maturation 
markers, but they expressed high levels of CD27 and low levels of CD11b. These results might 
explain why the systemic CXCR3 blocking treatment did not affect the proportion of NK cells 
in the CNS (Figure 7), as most of the CXCR3+ cells are actually ILC1s (Figure 4) and only a 
small fraction of immature NK cells express this chemokine receptor.  
The phenotype of the type ILC1s was further characterized in comparison with the NK 
cells of the CNS (Fig 11). Moreover, the modulation of some of the found markers was further 
evaluated in EAE mice (Fig. 12). Although CD127 (IL-7Ra) is a defining marker of helper ILCs, 
it was not expressed in all CNS ILC1s but only in a fraction (24 ± 2 %) (Fig. 11). A small 
proportion of NK cells also expressed CD127 (7 ± 1 %). Similarly, it has been reported that 
liver, skin, uterus and salivary gland ILC1s have a moderate or no expression of CD127 
(96,98). It was shown that contrary to ILC2 and ILC3, ILC1s are not affected by IL-7Ra 
deficiency, but that like NK cells, depend on IL-15 for their development and maintenance (17).  
CD90.2 (Thy1.2) was also expressed in ILC1s in high proportion (81 ± 4 %) (Fig. 11). 
This marker is expressed consistently in helper ILCs (7), however it is not an ILC exclusive 
marker since it is also expressed in T cells, hematopoietic stem cells and other non-lymphoid 
cells such as neurons (230,231). In this line, a low proportion of NK cells also expressed 
CD90.2 (39 ± 4%).  
CD69 is a tissue resident marker, it interacts with S1P1 inhibiting the response to the 
S1P gradient present in the bloodstream (123). In concordance, ILC1s homogeneously 
expressed CD69 (79 ± 2 %) while some NK cells expressed it in lower levels (12 ± 2 %) (Fig. 
11). CD69 expression significantly increased on NK cells in the EAE mice (Fig. 12). CD69 is 
also considered as an early activation marker. Its upregulation is therefore in line with an 
activation of NK cells in the EAE microinflammatory environment. CD69 upregulation on 
immune cells after activation contribute to their retention in the site of inflammation. CD103, 
an integrin that is expressed in intraepithelial ILC1s (60) was not expressed in the CNS-ILC1s.  
CD200R is an anti-inflammatory receptor expressed in myeloid cells, its expression has 
been found also in T and B cells (232), and only recently in ILC1s but not NK cells of the 
peritoneal cavity (62). Here, an expression of CD200R was also found in CNS-ILC1s (58 ± 
5%) but not NK cells (Fig. 11). In the CNS, CD200R is expressed in microglia and astrocytes 
and the ligand, CD200, is expressed in endothelial cells and neurons (233). The CD200R-
CD200 axis appears to be an immunomodulatory mechanism by which neurons suppress 
microglia activation. CD200 deficiency as well as the blockage of CD200R-CD200 interaction 
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result in a more severe EAE disease, (234–237). Conversely, the administration of a CD200R 
agonist attenuated EAE disease (238). The presence of CD200R in CNS-ILC1s might be 
therefore a mechanism to inhibit undesired immune responses of CNS resident ILC1s against 
neurons and support a homeostatic/immunomodulatory role of these cells.  
In general, ILC1s are considered to be non-cytotoxic, however, it was found that 
CNS-ILC1s express perforin (95 ± 1 %), albeit in lower levels than NK cells (perforin gMFI 
ILC1s = 2316; NK cells = 10561; p=0.006). In addition, TRAIL is an apoptosis inducing ligand 
that was also found to be homogeneously expressed on the CNS-ILC1s (81 ± 6%), and on few 
NK cells (8 ± 2 %) (Fig. 11). The expression of TRAIL is part of the ILC1 signature (239), low 
levels of perforin in ILC1s have also been reported. Tonsil intraepithelial ILC1s express perforin 
and are able to release lytic granules in cytotoxicity assays with tumor cell lines (60). Liver 
ILC1s are also perforinlow (56,240) and express TRAIL and are able, like salivary gland ILC1s, 
to mediate target cell killing via TRAIL (55,61,98). It was shown that neurons upregulate TRAIL-
R2 during the course of EAE, which make them vulnerable to TRAIL mediated killing by 
encephalitogenic T cells. The authors showed that a brain specific blockade of TRAIL reduced 
EAE severity as well as the transfer of TRAIL-deficient T cells (241). On the other hand, mice 
systemically treated with a blocking soluble TRAIL receptor (242) and TRAIL-deficient mice 
display a more severe EAE disease (243). In the TRAIL-deficient mice, a greater frequency of 
CD4+ Th1 cells, and a lower frequency of CD4+Foxp3+ Tregs was found compared to WT 
mice (243). In this line, various reports have shown that TRAIL is important to inhibit T cell 
activity by Tregs and NK cells, either by killing them or inhibiting their proliferation (244–247). 
In the same line, it was found that CNS-ILC1s homogeneously express DNAM-1 (96 ± 1 %) in 
much higher levels than NK cells (DNAM-1 gMFI ILC1s = 24927; NK cells = 1760; p<0.0001) 
(Fig. 11). DNAM-1 is another activating receptor that has been implicated in the killing of 
autoreactive T cells by NK cells (193). Of note, MS patients displayed lower levels of DNAM-1 
in NK cells and its ligand CD155 on activated T cells. Daclizumab treatment restored the 
expression of these proteins facilitating NK cell cytolitic activity against activated T cells in MS 
patients (193). Here, it was found that the expression of DNAM-1 was stable in the CNS-ILC1s 
during EAE, however, a downregulation of TRAIL on ILC1s was detected on EAE mice (Fig. 
12). TRAIL can be released in a soluble form from granules (248) or after being cleaved from 
the surface by cysteine proteases (249). In addition, it was shown that TRAIL death receptors 
are endocytosed together with bound TRAIL to regulate the apoptotic signaling (250). Thus, 
the downregulation of TRAIL on ILC1s might reflect either a cleavage to generate soluble 
TRAIL, or an internalization after being bound to the death receptors in target cells. 
In sum, the characteristic high expression of TRAIL and DNAM-1 in CNS-ILC1s 
suggest that they might be able to recognize and lyse activated T cells.  
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The chemokine receptor CXCR6 was also expressed homogeneously in all CNS-ILC1s 
(97 ± 0.8 %) but not on NK cells (Fig. 11). CXCR6 expression has been detected in the ILC1s 
of the liver, salivary glands and uterus (60,92,101,239) In the CNS, its ligand, CXCL16 is 
expressed in endothelial cells, astrocytes, microglia, and neurons (251,252) and its expression 
has been shown to be upregulated in vitro by IFN-γ and TNF-α. Furthermore, astrocytes 
release soluble CXCL16 upon inflammatory conditions (251) and an elevated concentration of 
CXCL16 has been found in the CSF of MS patients (253). Interestingly, the CXCL16-CXCR6 
axis promote neuroprotection in a model of glutamate exitotoxicity and cerebral ischemia 
(252,254). On the other hand, CXCR6+ NK1.1+ cells have been assigned a memory function 
in the liver and uterus (101,117). Liver memory NK cells – defined as CD45+NK1.1+Thy.1+, 
most likely representing ILC1s – mediate hapten-induced contact hypersensitivity responses, 
that is, they mount a memory response in the skin against haptens to which mice have 
previously been sensitized (255). Paust and colleagues showed that these memory NK cells 
are CXCR6+, that CXCR6 blockade abolish memory responses and that CXCR6-deficient NK 
cells are not able to transfer hapten sensitivity and survive poorly. CXCR6 did not mediate the 
antigen recognition but rather seemed to mediate memory NK cell homeostasis and survival 
through the engagement with CXCL16 that is constitutively expressed in hepatic sinusoidal 
endothelium (117). In the uterus, CXCR6+ ILC1s expanded in second pregnancies suggesting 
a pregnancy memory role of these cells, which are probably responding to the CXCL16 
expression by the trophoblast (101). Of note, the expression of DNAM-1 was also found to be 
essential for the differentiation of memory NK cells in response to MCMV infection (53). In sum, 
considering the expression of CXCL16 in the brain parenchyma, it is likely that CNS-ILC1s 
reside in close proximity with the brain cellular components where they can mediate 
neuroprotective and/or memory functions. Therefore, it would be of great interest to study the 
response of CNS-ILC1s to EAE relapses in the relapsing-remitting SJL model. In addition, it is 
likely that CXCR6 signaling is important to promote the survival and maintenance of CNS-
ILC1s, as it was shown in the liver ILC1s (117).  
Moreover, it was confirmed that CXCR3 is predominantly expressed on ILC1s (49 ± 4 
%) and that its expression is decreased on both NK cells and ILC1s during EAE disease (Fig. 
12). As shown in the experiments of the previous section, the internalization of CXCR3 seen 
on LN- and spleen-derived NK cells after encounter with CXCL10 (Fig. 5), should also apply 
to ILC1s. Hence, CXCR3 downregulation indicate that ILC1s might reside in locations where 
CXCL10 ligands are expressed during inflammation such as the choroid plexus (144) and the 
subventricular zone (SVZ), in which NK1.1+ cells have been found to accumulate at chronic 
stages of EAE (206). In that context, it was shown that SVZ neural stem cells (NSCs) were a 
source of IL-15 to sustain NK cells, however, a backlash effect of NK cell cytotoxicity against 
NSCs hindered recovery from chronic EAE. NSC were shown to downregulate the inhibitory 
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ligand Qa1 in chronic EAE, which may have made them more susceptible to killing by NK cells 
(206). Whether ILC1s express the same array of inhibitory receptors as NK cells, such as 
NKG2A that recognizes Qa1, is unclear, and how they respond to missing self signals is a 
matter of further investigation. 
In sum, the phenotypic profiling of CNS group 1 ILCs show that CXCR6, TRAIL, DNAM-
1high and CD200R are defining markers of ILC1s in this tissue, which hints into a homeostatic 
and immunomodulatory role of this subset in the CNS.    
The expression of integrins and other adhesion molecules on the surface of the cells is 
highly dynamic and might change upon stimulation. Here, it was confirmed that the distinction 
of the group 1 ILC subsets of the CNS by the surface expression of CD49a and CD49b was 
still valid in the context of neuroinflammation. The expression of nuclear Tbet and absence of 
Eomes was unchanged in the CD49a+CD49b- ILC1 population in EAE mice. Likewise, 
CD49a-CD49b+ NK cells from EAE mice expressed nuclear Tbet and Eomes in the same way 
as naïve mice. In the CD49a+CD49b+ intILC1s, a slight but non-significant increase of 
Tbet+Eomes+ cells was observed in the EAE mice (Fig. 12).  
It has been reported that ILC1s express a broader range of cytokines upon stimulation 
than NK cells, including IL-2, GM-CSF and TNF-α (56,61,96). Here, the expression of TNF-α 
and IFN-γ by the group 1 ILCs of the CNS was explored in vitro using cells derived from the 
CNS of naïve mice and EAE mice. When cells were stimulated with IL-15 and IL-12, a high 
proportion of NK cells and ILC1s expressed IFN-γ, but almost no TNF-α was detected. PMA 
and Ionomycin stimulation, in turn, elicited IFN-γ and TNF-α production. This was also the case 
in cells derived from the CNS of EAE sick mice. In concordance with previous reports, it was 
found that CNS-ILC1s produce significantly more TNF-α than NK cells, but they produced IFN-
γ in a similar way as NK cells. In addition, significantly more ILC1s were able to produce both 
TNF-α and IFN-γ at the same time (Fig. 13B). Altogether, the phenotypic and cytokine 
secretion profile substantiate a true ILC1 identity of the NK1.1+CD49a+ cells of the CNS. 
Importantly, it was found that the expression of cytokines in ILC1s did not increase in EAE sick 
mice compared to the naïve mice (Fig 13C). Since ILC1s provide an early source of cytokines 
during inflammation (62), an increase in ILC1 cytokine production might have occurred at onset 
or pre-onset stages of EAE. 
Next, it was interesting to determine the location of these group 1 ILCs within the CNS 
compartments. Their chemokine receptor profile supported a possible location in the brain 
parenchyma and the choroid plexus, indeed, ILC1s were found in those compartments and 
represented the most frequent population of the CD3-NK1.1+ cells. Interestingly, in the steady 
state, ILC1s were highly overrepresented in the choroid plexus (about 80% of NK1.1+ cells), 
while very few intILC1s and NK cells were found there. The ILC1s residing in the CP could 
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have a gatekeeper role, as it was previously shown for other IFN-γ secreting cells located in 
the CP. Specifically, it was shown that Th1 cells residing in the CP regulated the expression 
of trafficking molecules via IFN-γ secretion, which allowed the infiltration of immune cells during 
inflammation. Importantly, this regulation was shown to be favorable and necessary for the 
recovery from spinal cord injury by allowing the infiltration of beneficial monocytes (144). 
Furthermore, a shift towards a Th2 microenvironment in the CP was found in aged mice and 
was associated with cognitive decline (143). Similarly, CP-resident ILC1s might contribute to 
the beneficial type I IFN milieu that coordinates the selective trafficking of immune cells into 
the CSF. A gatekeeper function was also ascribed to ILCs present in the meninges, in one of 
the few reports that have addressed the contribution of ILCs to EAE pathology (207). In that 
study, Kwong and colleagues visualized numerous NKp46+ cells in the meninges of NKp46-
reporter EAE mice, and showed that they were present there even before disease onset. In 
addition, mice with a specific deletion of Tbet in NKp46+ cells (Tbx21f/f NKp46-Cre+), which 
caused a reduction of ILC1s and NK cells but not NCR+ ILC3s, displayed a delayed EAE onset 
after Th17 adoptive cell transfer, indicating a role of NKp46+ ILCs in controlling infiltration of 
Th17 cells into the CNS. Less CD4 cell infiltration in the parenchyma and less expression of 
metalloproteinases and chemokines in the meninges was found in those mice, indicating that 
NKp46+ ILCs in the meninges express factors that facilitate cell infiltration during inflammation. 
The effect pointed to the ILC1s, since NK cell-deficient mice (Eomesf/fNKp46-Cre+) did not 
display a delayed onset of Th17 adoptive cell transfer EAE (207). Here, it was found in 
concordance that the meninges contain the three group 1 ILC1 subsets, with a similar 
proportion of ILC1s (44%) and NK cells (35%). Interestingly, a significant increase on the 
numbers of all three group 1 ILCs was found only in the brain parenchyma in the EAE mice, 
with a notable increase in the numbers of intILC1s (p<0.001) and NK cells (p<0.01), which is 
in line with a recruitment of these cells into the brain parenchyma, where the myelin-targeted 
inflammation occurs. Besides an active cell recruitment from the CNS compartments into the 
parenchyma, an in situ cell proliferation in response to inflammation could explain the 
increased numbers of group 1 ILCs during EAE. Therefore, the cells that were actively 
proliferating were identified with the Ki67 marker in the whole CNS (Fig. 15).  That analysis 
revealed that only NK cells had an increased proliferation in the CNS of EAE mice compared 
to naïve mice. Since a fraction of intILC1s also are Eomes+, the proliferation on this subset 
was also analyzed, however, there was not a significant increase in the number of Eomes+ 
intILC1s nor a higher percentage of Ki67+ cells on the Eomes+ intILC1s. In concordance with 
the previous result of an increase of ILC1s and intILC1s on the brain parenchyma during EAE, 
an increase on the number of Tbet+Eomes- cells was still observed when analyzing the whole 
CNS. It is possible that a dilution effect of having examined the whole CNS instead of each 
compartment separately could account for the lack of increased Ki67+ cells in the ILC1s and 
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intILC1s. However, it is also possible that the increased numbers of intILC1s and ILC1s in the 
brain parenchyma are caused by a conversion of NK cells into intILC1s/ILC1s under the 
inflammatory microenvironment of the EAE brain. It has been shown with in vitro and in vivo 
experiments that TGF-β can induce the differentiation of NK cells into ILC1s cells 
(68,92,256,257). TGF-βs are multifunctional cytokines that play a regulatory role in the 
initiation and resolution of immune responses. TGF-β1 is present in normal human brain tissue, 
astrocytes and microglia and has been found in active demyelinating lesions of MS patients 
(258). In the EAE model, TGF-β1 secretion by astrocytes and microglia is upregulated at early 
stages of disease (259,260). Therefore, it is likely that some infiltrating NK cells respond to it 
by converting into ILC1s via an intILC1s stage, which might explain the great increase on 
intILC1 numbers in the brain during inflammation.  
In conclusion, the results of the present thesis provide new evidence of the existence of 
diverse group 1 ILCs in the healthy CNS of mice. The phenotypical characterization of CNS-
ILC1s strongly suggest that they take active part as immunomodulatory, neuroprotective and 
gatekeeping agents in the CNS parenchyma and barriers. Finally, this work offers a foundation 
for further investigation of the implication of ILCs on CNS immunity and homeostasis.  
 
7.3 Graphical summary 
 
Figure 16. Phenotype of CNS-ILC1s and NK cells. ILC1s in the CNS express the transcription factor 
Tbet, have few intracellular perforin and secrete TNF-α and IFN-γ. They are characterized by the surface 
expression of CXCR6, CXCR3, DNAM-1, TRAIL, CD200R, CD49a, CD69 and CD27. NK cells express 
Eomes in addition to Tbet, have high levels of intracellular perforin and secrete predominantly IFN-γ. In 
overlap with ILC1s, they express lower levels of DNAM-1 and some express CD127 and CD90. They 
can have an immature phenotype characterized by CD27 but most of them express the maturation 
marker CD11b and express the integrin CD49b. In addition, they show a higher proliferative response 
than ILC1s in response to neuroinflammation.  
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7.4 Outlook 
 
The long-term tissue residency and lack of recirculation of ILCs in diverse organs has 
been demonstrated multiple times with parabiosis experiments (61,62,67,92,96,105,261). 
Hence, in the present work, it is assumed that the newly described ILC1s of the CNS are tissue 
resident, a possibility that is substantiated by their expression of the tissue resident markers 
CD49a and CD69. However, that remains to be confirmed with parabiosis experiments. Of 
special interest would be the comparison of the recirculation dynamics of ILC1s with the NK 
cells, which are assumed to originate from the periphery but whose mobilization and retention 
in the CNS might differ from peripheral organs due to the immunoprivileged nature of the CNS. 
Recently, it was reported that hapten sensitization induced the mobilization of memory-ILC1s 
to the skin-draining LNs in a CXCR3-dependent manner. Memory-ILC1s were then recruited 
to the liver in a CXCR6-dependent manner (262). These findings challenge the view of an 
obligate tissue residency of ILCs and highlight the need to study the mobilization of ILCs during 
inflammation. Thus, the mobilization of the presently described CXCR3+CXCR6+ ILC1s 
between the CNS and the CNS-draining lymph nodes deserves consideration. 
The elucidation of factors that maintain and support ILC1 functions in the CNS are of 
great relevance. Microglia display a TGF-β-dependent gene expression signature and they are 
absent in TGF-β1-deficient mice (263). Similarly, the maintenance of ILC1s in the CNS might 
be dependent on the TGF-β1-rich environment of the CNS, which is in concordance with 
reports of salivary gland ILC1s (92). In addition, it has been shown that NSCs are able to 
secrete IL-15, and that IL-15 is increased in the brain in conditions like enriched environment 
(206,264), further supporting a CNS intrinsic mechanism for ILC1 maintenance. In the same 
line, important questions to address are the pinpointing of the appearance of ILC1s or ILC 
progenitors in the tissue during CNS development, and whether CNS-ILC1s are replenished 
in the tissue by the conversion of NK cells into ILC1s.   
Based on the phenotypic profile of the ILC1s described in the present thesis, the 
proposed roles of CNS ILC1s are a gatekeeping function in the brain barriers such as the CP 
and meninges and a neuroprotective role in the brain parenchyma. The role of ILC1s in the 
development of EAE was not explored in the present thesis. ILC1s could have a detrimental 
role on EAE by allowing the passage of autoreactive T cells as reported by Kwong (207), 
conversely, a protective role by limiting inflammation and lysing autoreactive T cells is also 
possible. Further studies with a ILC1-deficient mouse, such as the Hobbit knock-out mice, 
would shed light into the definite role of ILC1 in the onset and development of EAE. In addition, 
it is of great interest to study the response of ILC1s in pre-onset and chronic stages of EAE, 
since ILC1s were found to act early in inflammation by being the first source of IFN-γ in the 
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context of viral infection (62), but have also been associated with delayed, long-term memory 
responses (262).  
In addition, since ILC1s orchestrate type I responses, it is of key importance to 
investigate the role of CNS-ILC1s in the clearance of viral infections, such as meningitis; and 
the control of brain tumors, such as glioma. 
To conclude, the strategic location of ILC1s in the CNS open new avenues in the 
investigation of the cross talk between the immune system and the nervous system. Recently 
recognized is the fact that ILCs are able to respond to or produce neuropeptides, 
neurotransmitters, neurotrophic factors and hormones. For example, group 1 ILCs express the 
glucocorticoid receptor whose activation has been shown to inhibit IFN-γ production (265). In 
addition, it has been reported that NK cells are able to produce acetylcholine (266). Therefore, 
further research should capture details of the communication between group 1 ILCs, glia and 
neurons.  
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